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The risk of cardiovascular events increases in individuals with elevated plasma triglyceride (TG) levels,
therefore advocating the need for efﬁcient TG-lowering drugs. In the blood circulation, TG levels are
regulated by lipoprotein lipase (LPL), an unstable enzyme that is only active as a non-covalently asso-
ciated homodimer. We recently reported on a N-phenylphthalimide derivative (1) that stabilizes LPL
in vitro, and moderately lowers triglycerides in vivo (Biochem. Biophys. Res. Commun. 2014, 450, 1063).
Herein, we establish structureeactivity relationships of 51 N-phenylphthalimide analogs of the screening
hit 1. In vitro evaluation highlighted that modiﬁcations on the phthalimide moiety were not tolerated and
that lipophilic substituents on the central phenyl ring were functionally essential. The substitution
pattern on the central phenyl ring also proved important to stabilize LPL. However, in vitro testing
demonstrated rapid degradation of the phthalimide fragment in plasma which was addressed by
replacing the phthalimide scaffold with other heterocyclic fragments. The in vitro potency was retained
or improved and substance 80 proved stable in plasma and efﬁciently lowered plasma TGs in vivo.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coronary Artery Disease (CAD) is a medical term encompassing
a set of conditions responsible for the narrowing and hardening of
blood vessels. CAD is classiﬁed as theworld's leading cause of death
and, therefore, the prevention, control and treatment of its asso-
ciated risk factors remain essential [1,2]. For instance, the proba-
bility of developing CAD increase signiﬁcantly with age [3], familymetabolism and excretion;
in; BINOL, 1,10-bi-2-naphthol;
ease; EC50, effective concen-
activity relationship; TG, tri-
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Masson SAS. This is an open accesshistory [4], obesity [5], diabetes [6], high blood pressure and/or
high blood cholesterol levels [7]. Likewise and even though it has
long been debated, hypertriglyceridemia is an independent risk
factor of CAD [8,9]. Abnormally elevated plasma triacylglycerol (TG)
levels is a frequently encountered lipid disorder closely associated
with other CAD risk factors [10,11].
Plasma TGs originate from exogenous and endogenous sources.
Dietary TGs are packed into large lipoprotein particles (chylomi-
crons) in the intestine whereas endogenous TGs are assembled into
very low-density lipoproteins (VLDLs) in the liver. After entering
the blood circulation these TG enriched lipoproteins are processed
by lipoprotein lipase (LPL), a TG speciﬁc hydrolase enzyme [12e14].
The released free fatty acids and monoglycerides are stored or
directly utilized for energy production in adipose or muscle tissues,
respectively. The remnant lipoproteins are absorbed by the liver or,
in the case of VLDL remnants, they are further processed into low-
density lipoproteins (LDL).article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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[12,15]. The enzyme, which is only active as an unstable non-
covalently associated homodimer, is produced and secreted from
parenchymal cells. LPL is then transported and anchored to its site
of action at the luminal surface of endothelial cells in capillaries
[14]. Several endogenous factors such as angiopoietin-like protein
(ANGPTL) 3 and 4 regulate LPL activity [15,16]. ANGPTL3 is reported
to inhibit LPL [17] whereas ANGPTL4 directly promotes the disso-
ciation of the active homodimer into inactive monomeric species
[18].
Causes for abnormally elevated plasma TG levels are gathered
into two categories: familial and acquired hypertriglyceridemia
[10]. Familial hypertriglyceridemia is believed to be a consequence
of an accumulation of inherited deleterious alleles in genes regu-
lating lipoprotein catabolism, including LPL [19]. The condition is
said acquired when it is induced by environmental factors such as
obesity, type 2 diabetes mellitus or high alcohol consumption.
Lifestyle changes, e.g. low fat diet, physical activity and alcohol
restriction usually lower plasma TG levels in hypertriglyceridemic
patients; however, for patients for whom lifestyle changes have
been ineffective, medication with ﬁbrates, niacin and/or n-3 fatty
acids may be necessary [20].
Herein, we report on the design, synthesis and evaluation of
small molecules that stabilize LPL in the presence of ANGPTL4 and,
therefore, prevent the dissociation and inactivation of homodi-
meric LPL. As a result, a signiﬁcant increase in LPL-mediated hy-
drolysis was seen in vitro with a number of compounds.
Structureeactivity relationships (SAR) based on the screening hit
were established and the optimized compounds were found to be
efﬁcacious in vivo.2. Results and discussion
High throughput screening of 17,340 compounds provided the
foundation for this medicinal chemistry program [21]. The
screening hit 1 (Fig. 1a), a substituted N-phenylphthalimide, was
selected as starting point on the basis of its positive effects on LPL
stability. Compound 1 preserved LPL activity at 37 C or when
incubated at room temperature with the enzyme in the presence of
ANGPTL4. Chemical diversity around the N-phenylphthalimide
scaffold (Fig. 1b) can be achieved by starting from readily available
building blocks. All compounds in the present study were investi-
gated for effects on LPL activity and stability, in the presence of
ANGPTL4, according to previously described protocols [21].
The synthesis of 1 was straightforward and in good yields
(Scheme 1). Compound 2 was converted to the corresponding acid
chloride upon treatment with oxalyl chloride. Thereafter, coupling
with p-toluidine provided 3 in 90% yield. Direct amination of 3with
piperidine under basic conditions yielded 4 (94%) [22]. Subsequent
reduction of the nitro group using tin dichloride in reﬂuxing
ethanol [23] or sodium borohydride and palladium on charcoal inFig. 1. a) Screening hit 1 [21] and b) chemical diversity on themethanol [24] afforded 5 in nearly quantitative yields. Finally, the
condensation reaction between aniline 5 and a substituted phthalic
anhydride (6) in reﬂuxing glacial acetic acid gave 1 in 89% yields
[25].2.1. Relevance of the carboxylic acid
Compound 7, which only differs from the selected hit (1) by the
absence of the carboxylic acid functional group, was also evaluated
during the primary screen (Table 1) [21]. Interestingly, it could not
preserve LPL activity which indicates that a substituent on the
phthalimide moiety (R1 in Fig. 1b) is essential. To probe the role of
the carboxylic acid, a set of compounds inwhich the carboxylic acid
present in 1 was moved or replaced with other functional groups
was ﬁrst investigated (Table 1).
The synthesis of the N-phenylphthalimide derivatives followed
the synthetic route to 1 (Scheme 1), using the appropriate phthalic
anhydride derivatives in the last step (83e97% yields) [25]. Some of
the target compounds necessitated an additional transformation.
The methyl ester 12 was conveniently obtained in high yield (97%)
by reacting 1 with trimethylsilyldiazomethane [26]. The carbox-
amide derivative 11 was synthesized by treatment of 1 with oxalyl
chloride to form the corresponding acid chloride and the activated
carboxylic acid was then reacted with hexamethyldisilazane and
provided 11 in 11% yield after recrystallization. Finally, microwave-
assisted cyanation of 8 using copper cyanide as the nitrile source
gave 10 in 24% yield.
The substances were subsequently evaluated for stabilization of
LPL activity [21]. In brief, ANGPTL4 and LPL were added to a
phosphate buffer solution containing the compounds previously
dissolved in DMSO and a detergent. The mixtures were incubated
for 10 min at 25 C and the remaining LPL activity was determined
by addition of a substrate mix containing Intralipid®. LPL-mediated
hydrolysis was terminated after 45 min and the released free fatty
acids were quantiﬁed using a titration kit (NEFA HR2 from Wako
Chemicals). All enzymatic activity measurements were normalized
to DMSO controls where 100% represent LPL incubated without
ANGPTL4.
The effect of the compounds on LPL activity is summarized in
Table 1. Solely 1 contributed to a signiﬁcantly greater enzymatic
activity. Indeed, a replacement of the carboxylic acid by another
small functional group at the position 5 of the phthalimide (com-
pounds 7e12) resulted in the limited or absence of LPL-mediated
hydrolysis. The low activity of 11 at 25 mM underlined the impor-
tance of having an acidic functional group (carboxylic acid in 1 vs.
carboxamide in 11). It also demonstrated that electron-
withdrawing substituents have no direct effect on the compound
potency. As expected from the initial screen, 7 was conﬁrmed
inactive. Similarly, moving the carboxylic acid to position 4 of the
phthalimide (13) completely suppressed the effect observed for 1.
These results are conspicuous and evidence the need of having aN-phenylphthalimide scaffold investigated in this study.
Scheme 1. Synthesis of 1.
Table 1
Effect of carboxylic acid substitution on LPL stabilization.
ID Structure % of controla (C in mM)
3.12 6.25 12.5 25
1 NA NA 90.0 ± 16.0 93.8 ± 16.3
7 NA NA NA NA
8 NA NA NA NA
9 NA NA NA 11.4 ± 15.8
10 NA NA NA NA
11 NA NA NA 3.5 ± 0.6
12 NA NA NA NA
13 NA NA NA NA
a See experimental section for details. NA: not active.
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quently, it was decided that newly designed compounds all should
include a carboxylic acid functional group at this position.2.2. Substituent scrambling
Efforts to optimize the screening hit then focused on thesubstituents on the central phenyl ring (R2 and R3 in Fig. 1b). A
series of seven analogs that present a scrambling of the two sub-
stituents around the central phenyl ringwere synthesized (Table 2).
In addition, three other substances where the 1-piperidinyl group
in compound 23 was replaced by a chloride (14), a phenyl- or tol-
ylamino derivative (15 and 16, respectively) were also analyzed.
Compounds 17e22 were prepared using the same synthetic
route as in Scheme 1 with use of the appropriate starting materials.
A different synthetic strategy was however adopted for the prep-
aration of compounds 15, 16 and 23, using 3-bromo-5-
aminobenozoic acid (24) as starting building block. During the
amide coupling and the direct amination reactions (Scheme 2, steps
a and b/c respectively), the unprotected amino group present in 24
would compete with the reacting amines and therefore a non-
negligible amount of homo-coupling products would form. To
circumvent this problem 24 was conveniently converted into the
corresponding formamidine product upon reaction with the Vils-
meier reagent [27]. A subsequent amide coupling with p-toluidine
formed 25 (60%), in a one-pot procedure. Compound 25 was sub-
sequently reacted with aromatic or aliphatic amines under Buch-
wald coupling conditions [28,29] and after formamidine cleavage in
reﬂuxing ethylenediamine [27], compounds 28e30were isolated in
53e73% yields. The condensation reaction between the resulting
amines and 6 yielded the ﬁnal products (50e62%).
Modiﬁcation of the substitution pattern of 1 generally proved
detrimental, or at best non-beneﬁcial, for LPL stabilization (Tables 1
and 2). Thus, displacing the p-tolylcarbamoyl substituent to posi-
tion 2 of the central phenyl ring (19) did not improve the hit po-
tency. Moving the 1-piperidinyl group to position 5 (23) or 6 (20) of
the ring considerably or slightly reduced LPL activity, respectively.
Interestingly, reversing the substituents (21) resulted in a com-
pound with low activity. Sterically congested compounds 18 and 22
were also demonstrated poorly active. Finally,17 showed a reduced
potency compared to the screening hit. As a result, the substitution
pattern of 1 was concluded as the pattern of choice for LPL
stabilization.
The set of modiﬁed derivatives of 23 (14e16) also provided
valuable information. While 14 proved inactive, the replacement of
1-piperidinyl by a phenylamino group (15) improved the potency of
the compound in comparison to 23. However, elongation of the
phenylamino substituent of 15 with a methyl group (16) caused a
dramatic loss of activity, thus suggesting that larger groups are not
tolerated.2.3. Substituent variation
A set of 33 compounds with the 1,3,4 pattern on the central
phenyl ring (cf. Fig. 1) was designed and synthesized (Table 3). N-
Phenylphthalimide (31), despite the absence of a carboxylic acid
Table 2
Effect of substituent scrambling on LPL stabilization.
ID Structure % of controla (C in mM)
3.12 6.25 12.5 25
14 NA NA NA NA
15 NA 4.2 ± 0.8 73.1 ± 2.3 89.4 ± 3.2
16 NA 5.0 ± 0.8 7.0 ± 1.2 24.6 ± 3.5
17 NA NA NA 96.7 ± 5.5
18 NA NA NA 7.3 ± 2.6
19 NA NA 55.1 ± 4.5 36.3 ± 3.7
20 NA NA 81.3 ± 5.7 79.0 ± 4.0
21 NA NA NA 14.1 ± 2.9
22 NA NA NA 13.5 ± 2.7
23 NA NA NA 32.6 ± 1.4
a See experimental section for details. NA: not active.
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viously reported hypolipidemic activity in mice [30]. Challenging
31 in our in vitro assay would indicate a similar or different mode of
action than our analogs. For comparison 32, the carboxylated
version of 31, was also evaluated. The target compounds were
synthesized as described in Scheme 1 using of the appropriate
building blocks. For compound 54, O-alkylation was achieved in
75% yield by treating 3 with the alcohol derivative under basic
conditions in DMSO [31].
Table 3 presents the effect on LPL activity of one or a combina-
tion of two modiﬁcations at the central phenyl ring in respect to 1
(Table 1). Importantly, the previously reported 31 and 32 proved
completely inactive under our experimental conditions, thussuggesting that 1 and the other active analogs might preserve LPL
activity via a different mechanism.
The introduction of a more polar substituent (51e54 and 63)
resulted in a complete loss of LPL activity. Similarly, 55, 56 and 64
that have an electron donating or electron withdrawing group on
the central fragment were not active. It was not surprising to ﬁnd
that the combination of two unfavorable modiﬁcations (45 and 46)
resulted in inactive analogs. Also, the replacement of the methyl
group on the carbamoyl substituent with a methyl-ether (34)
decreased the compound potency.
Continuing the analysis on the carbamoyl substituent, the
addition of a chloride (48) caused a signiﬁcant increase in potency.
However, the corresponding ﬂuoride analog 50 did not exhibit any
enhanced potency in comparison to the screening hit. Likewise,
triﬂuoromethyl group in 35 and 49 did not contribute to LPL sta-
bilization. Benzylic (44) and aliphatic (47) substituents were found
inactive and less potent than 1, respectively. Removal of the methyl
group (33) signiﬁcantly reduced LPL-mediated hydrolysis whereas
its shift (36) decreased LPL activity. Interestingly, increasing the
bulkiness of the substituent (37, 39e40 and 43) proved favorable at
6.25 mM; however, the efﬁcacy of the compounds remained rela-
tively low (71% of control) at higher concentrations regardless to
the size of the substituent.
Substitution of the 1-piperidinyl moiety with a phenylamino
group (57) was conﬁrmed as a beneﬁcial transformation for LPL
activity. Compounds 38, 41e42 and 58 showed similar potencies as
57 and, therefore cumulative effects resulting from two favorable
modiﬁcations were not observed. Finally, the aliphatic derivatives
(59e62) provided valuable information. Short aliphatic chains (59
and 62) showed a detrimental effect on LPL activity whereas a
longer chain (60) enhanced the compound's potency to stabilize
LPL. However, further elongation of the tail (61) almost turned the
compound inactive, thus, probing the importance of the length of
the aliphatic chain.
Several compounds e.g. 41, 42, 58, reach a plateau at the two or
three highest concentrations tested. This could possibly be due to
low solubility or that these compounds act as partial agonists.
2.4. Evaluation of the in vitro plasma stability
Screening hit 1 was selected as model compound for the ab-
sorption, distribution, metabolism and excretion (ADME) proﬁling
of the N-phenylphthalimide derivatives. Unfortunately, 1 rapidly
degraded during the initial plasma protein binding study (2%
remaining after 4 h; see Experimental section for details). To verify
the poor stability, compound 1 was incubated and sampled over
24 h in human plasma which showed a short half-life (t1/2 ¼ 1.5 h).
The degradation mechanism was investigated by LCeMS/MS and
the ﬁrst and second metabolites were identiﬁed as the partially (65
and 66) and fully (5) hydrolyzed N-phenylphthalimide derivatives
(Table 4). Thus, 65 was formed predominantly (51% after 24 h)
while 66 and 5 were produced in lower quantities (24% and 23%
after 24 h, respectively).
In order to establish whether the metabolites could stabilize
LPL, they were synthesized and evaluated in our enzymatic assay
(Table 4). Regioisomers 65 and 66were obtained by addition of 5 to
anhydride 6 in acetic acid. After completion of the reaction, the two
regioisomers were separated using HPLC. Despite a mild effect on
LPL activity at 25 mM, compounds 65 and 66 remained less potent
than 1. The second metabolite (5) was found completely inactive in
our in vitro assay. Although these results highlight the beneﬁcial
effect of the rigid bicyclic scaffold over the ring-opened structures,
investigations on the N-phenylphthalimide compounds were dis-
continued as a consequence of their poor plasma stability. The
previously reported plasma TG lowering-effect of compound 1 in
Scheme 2. Synthesis of 15, 16 and 23.
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substances (1 þ metabolites) rather than the effect of 1 alone [21].
Consequently, the intrinsic potency of compound 1 was probably
underestimated in vivo.2.5. Design and synthesis of compounds stable in plasma
A set of compounds (Table 5) where the hydrolysis-prone
phthalimide fragment was replaced by other bicyclic scaffolds
was designed and synthesized. The selected heterocyclic rings
included benzimidazole 71, benzofuran 77, indole 78 and indazole
80e82 derivatives.
Compound 71 was synthesized in four steps starting from in-
termediate 5 (Scheme 3). The aniline derivative was converted into
aryl bromide 67 (90%) via a Sandmeyer reaction [32]. Halogen ex-
change using a copper-catalyzed procedure provided aryl iodide 68
in excellent yields [33]. Benzimidazole 70 was prepared in mod-
erate yields by direct arylation of 69 with 68 [34]. Subsequent
methyl ester hydrolysis under basic conditions yielded the target
compound (71, 90%).
Benzofuran and indole derivatives were prepared using the
synthetic route displayed in Scheme 4. Cross-coupling reaction
between aryl bromide 67 and trimethylsilylacetylene gave 72 in
60% yields after cleavage of the trimethylsilyl group [35]. A cascade
reaction involving a Sonogashira coupling between aryl iodide 73
or 74 and acetylene 72 followed by an intramolecular ring-closure
yielded benzofuran (75, 67%) and indole (76, 51%) derivatives,
respectively [36]. In this reaction the triﬂuoroacetyl leaving group
in 74 is needed for the ring-closure to occur during the coupling.
Subsequent methyl ester hydrolysis yielded the targeted benzo-
furan 77 (80%) and indole 78 (77%).
2H-Indazole derivatives 80e82were synthesized according to a
previously reported one-pot three-component procedure (Scheme
5) [37]. With our substrates, higher yields were however obtained
when the imine intermediate was synthesized separately. The
imine was prepared by reﬂuxing 5 and 79 [38] in ethanol.
The newly synthesized compounds were tested for stabilization
of LPL (Table 5). Compound 71 was evaluated as the weakest LPL
stabilizer of the series with a moderate effect on LPL activity at
25 mM. At low concentrations, the benzofuran scaffold in 77 provedbeneﬁcial over the phthalimide fragment in 1 and the indole de-
rivative 78 appeared potent. However, a drop in LPL activity was
observed for both compounds at 25 mM. The underlying reason is
most likely precipitation of the substances due to poor aqueous
solubility. Indazole isomers 80 and 81 were found to have similar
potency as 1. Interestingly, the shift of the carboxylic acid from
position 5 (81) to position 6 (80) did not affect the compound
ability to stabilize LPL. In order to verify the importance of the
carboxylic acid group in this compound class, 82 was investigated
and found inactive in agreement with the previous SAR.
The results depicted in Table 5 clearly demonstrate that het-
erocyclic fragments can efﬁciently replace the phthalimide scaffold.
In order to validate our optimization strategy, the drug-likeness of
compounds 77 and 80 was subjected to ADME proﬁling in vitro
(Table 6). Unlike 1, the substances proved stable in human plasma
(>93% stability). Both compounds strongly bound to plasma pro-
teins with <0.01% of estimated unbound fraction (see Experimental
section for details). The high protein binding indicates a limited
tissue exposure, which could be advantageous since LPL is oper-
ating in plasma. The kinetic solubility of compounds 77 and 80was
tested in phosphate buffered saline solution at neutral and acidic
pH (Table 6). Because of the presence of lipophilic substituents on
their core structure, 77 and 80 were expected to be poorly soluble
in aqueous solution. The experimental measurements conﬁrmed
this hypothesis. Ionization of the acid function at pH 7.4 (<2 mM for
both substances) or the apparent protonation of the different basic
functions at pH 1.2 (7 mM for 77; <2 mM for 80) did not signiﬁcantly
improve the solubility.
In vitro permeability was measured from transport rates across
Caco-2 cell monolayers as previously reported [39]. Compounds 77
(Papp value ¼ 1.2  106 cm/s) and 80 (Papp value¼ 23 106 cm/s)
had a moderate and high intestinal permeability in the absorptive,
apical to basolateral direction (aeb), respectively. Comparable
permeability coefﬁcients were obtained in the secretory, baso-
lateral to apical (bea) direction. Calculation of the efﬂux ratios
(E ¼ bea Papp/aeb Papp) indicated that no apparent active efﬂux
interfered with the transport of either 77 (E ¼ 1.5) or 80 (E ¼ 1.4).
Incubation in human livermicrosomes showed very highmetabolic
stability for 77 (t1/2 >80 h, CLint <17 mL/min/mg) and 80 (t1/2 >80 h,
CLint <17 mL/min/mg) which thus indicates a very low risk for
Table 3
Effect of substitutions at the core fragment on LPL stabilization.
ID Structure % of controla (C in mM) ID Structure % of controla (C in mM)
3.12 6.25 12.5 25 3.12 6.25 12.5 25
31 NA NA NA NA 48 NA 66.8 ± 4.8 73.0 ± 4.3 69.8 ± 5.4
32 NA NA NA NA 49 NA 19.4 ± 0.4 42.2 ± 0.7 65.8 ± 1.7
33 NA NA NA 57.0 ± 2.6 50 NA NA 53.3 ± 1.2 72.1 ± 1.1
34 NA NA NA 43.8 ± 6.8 51 NA NA NA NA
35 NA NA 54.6 ± 0.7 81.6 ± 1.1 52 NA NA NA NA
36 NA NA 38.6 ± 5.2 56.6 ± 5.2 53 NA NA NA NA
37 NA 32.4 ± 2.2 36.5 ± 2.8 47.0 ± 2.3 54 NA NA NA NA
38 NA 45 ± 2.3 61.5 ± 3.8 73.8 ± 3.6 55 NA NA NA NA
39 NA 55.6 ± 3.8 71.0 ± 3.9 53.1 ± 2.5 56 NA NA NA NA
40 NA 9.2 ± 1.9 63.4 ± 1.6 71.0 ± 1.7 57 NA 57.2 ± 8.6 80.1 ± 8.2 94.4 ± 11.1
41 NA 37.6 ± 2.2 60.3 ± 3.8 60.0 ± 2.2 58 NA 44.3 ± 1.2 63.9 ± 3.7 52.2 ± 6.6
42 NA 44.1 ± 3.5 59.1 ± 4.0 52.5 ± 3.2 59 NA NA NA 49.5 ± 4.7
43 NA 60.1 ± 2.3 63.3 ± 2.7 68.5 ± 3.4 60 NA 60.6 ± 4.5 47.1 ± 3.8 67.2 ± 4.3
44 NA NA NA NA 61 13.6 ± 5.8 5.9 ± 1.3 10.0 ± 1.6 19.2 ± 1.6
45 NA NA NA NA 62 NA NA 6.2 ± 0.4 39.7 ± 1.8
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Table 3 (continued )
ID Structure % of controla (C in mM) ID Structure % of controla (C in mM)
3.12 6.25 12.5 25 3.12 6.25 12.5 25
46 NA NA NA NA 63 NA NA NA NA
47 4.0 ± 0.6 19.3 ± 3.2 31.8 ± 11.5 67.8 ± 4.4 64 NA NA NA NA
a See experimental section for details. NA: not active.
Table 4
Effect of the ﬁrsts and second metabolites on LPL stabilization.
ID Structure % of controla (C in mM)
3.12 6.25 12.5 25
5 NA NA NA NA
65 NA NA NA 38.8 ± 6.6
66 NA NA NA 30.6 ± 15.5
a See experimental section for details. NA: not active.
Table 5
Effect of the new heterocyclic compounds on LPL stabilization.
ID Structure % of controla (C in mM)
3.12 6.25 12.5 25
71 NA NA NA 49.0 ± 1.7
77 NA 49.8 ± 2.5 76.0 ± 3.5 67.9 ± 3.3
78 35.0 ± 3.7 100.8 ± 2.2 85.5 ± 5.7 24.5 ± 2.8
80 NA 16.0 ± 1.9 75.6 ± 6.1 97.0 ± 6.2
81 NA 11.2 ± 1.2 90.6 ± 6.2 89.7 ± 6.4
82 NA NA NA NA
a See experimental section for details. NA: not active.
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were also tested in freshly prepared human hepatocytes, where
additional drug metabolizing enzymes are present and where 77
(t1/2 ¼ 40 min, CLint ¼ 35 mL/min/106 cells) showed a higher degree
of metabolism. In contrast, 80 (t1/2 > 2 h, CLint ¼ 12 mL/min/
106 cells) proved stable also under the in vivo-like conditions in the
human hepatocytes. In summary, the lead optimization was suc-
cessful. Further, the compounds are drug-like with regards to the
predicted oral drug space [42].
Compound 80, its regioisomer 81 and the screening hit 1 were
then further investigated in vitro by doseeresponse analysis and
determination of EC50 values (see the Supporting information for
doseeresponse curves). EC50 values were found to be 6.0 mM (80),
5.0 mM (81) and 6.6 mM (1) showing that the compounds have
similar potencies and reach full efﬁcacy.
2.6. Previously reported hypolipidemic agents
Our approach to the discovery of new and potent hypo-
triglyceridemic agents offers the advantage to assess the in vitro
evaluation of the target compounds. LPL is unstable and difﬁcult to
handle. Therefore, in vivo studies are often privileged.Wewanted to
investigate whether previously known lipid lowering compounds
could stabilize LPL in our enzymatic assay. As discussed above, N-
phenylphthalimide 31 and the carboxylated analog 32 (Table 3),
which belongs to the same class of compounds as our screening hit,
were inefﬁcient in our assay thus suggesting that 1 and the other
active analogs preserve LPL activity via a different mechanism than
31. Other LPL activators (Fig. 2), including Ibrolipim [43,44], also
known as NO-1886, some 5-ﬂuoro-1H-indole-2-carboxamides de-
rivatives [45] and C10 that was recently reported as an LPL agonist
preserving the enzyme from inhibition by ANGPTL4 [46] were
tested in our system. None of these substances proved active at
25 mM in our in vitro assay, conﬁrming that the LPL-activating
mechanisms are different compared to the stabilizing effects of
the compounds described in this study.
2.7. In vivo investigation
In order to compare the in vivo efﬁcacy with the in vitro ﬁndings
on our compounds, 1, 71, 77, 78, 80, 81 and vehicle only were
administered through intraperitoneal (i.p.) injections to mice
(n ¼ 8/group), once daily for 4 days (10 mg/kg body weight per
injection). Before the last injection the mice were fasted overnight.
On the next morning they were given a last injection and after
60 min they were challenged with an oral olive oil gavage to
monitor postprandial lipid clearance. In the fasting state 80was the
only compound that caused signiﬁcantly lower TG levels than the
vehicle control (Fig. 3). However, 60 min after the gavage all ani-
mals but those receiving compound 1 had signiﬁcantly lower
plasma TG levels than the vehicle control. The low plasma stability
Scheme 3. Synthesis of 71.
Scheme 4. Synthesis of 77 and 78.
Scheme 5. Synthesis of 80.
Table 6
In vitro ADME parameters of hit compound 1 and optimized hits 77 and 80.
ID Solubility (mM) Caco-2 Pappa
(106 cm/s)
Efﬂux PPBa (%) CLinta (ml/min/mg)
pH 1.2 pH 7.4 (aeb) (bea) E ¼ ðbaÞðabÞ fua Stability HLMa MLMa HHEPa
1 e 80 12 31 2.7 e 2 e e e
77 7 <2 1.2 1.8 1.5 <0.01 93 <17 e 35
80 <2 <2 23 31 1.4 <0.01 96 <17 <12 <10
a Abbreviations: Papp (apparent permeability); PPB (plasma protein binding); fu (fraction unbound); CLint (intrinsic clearance); HLM/MLM (human/mouse liver micro-
somes); HHEP (human hepatocytes).
R. Caraballo et al. / European Journal of Medicinal Chemistry 103 (2015) 191e209198of 1, described above, is most likely the reason for the modest ef-
ﬁcacy of this compound [21]. At 120 min, a similar patternwas seen
compared to vehicle control. At 180 min, the TG values for most
compounds were signiﬁcantly lower than for compound 1. These
data demonstrate that compounds 71, 77, 78, 80 and 81 are superior
to the previously reported compound 1 for accelerating post-
prandial lipid clearance. In early studies, a single i.p. injection was
found to be less efﬁcient than the repeated injections for 4 days inlowering TG levels (data not shown).
Potentially the TG lowering effect could the result of transcrip-
tional activation [47]. To address this we proﬁled compound 80 for
agonist activity against a set of nuclear receptors (see Experimental
section for details). For all receptors the EC50 values exceeded
100 mM. These results supported our theory that the efﬁcacy in vivo
of the compounds is due to a direct effect on LPL.
The most commonly used drugs for lowering TG are niacin,
Fig. 2. Previously reported LPL activators tested in our enzymatic assays a) Ibrolipim (NO-1886); b) 5-ﬂuoro-1H-indole-2-carboxamides and c) LPL agonist C10.
Fig. 3. Oral lipid gavage on wild type mice. Mice (n ¼ 8/group) were treated as indi-
cated once daily for 4 days with i.p. injections. One hour after the last injection mice
were given a 200 ml oral lipid gavage. Plasma TG levels were investigated at the
indicated time points. Data for TG are mean values with standard deviation. A one-way
ANOVA Tukey's multiple comparison test was used for statistical analysis. *, ** and ***
correspond to p-values of 0.05, 0.01 and 0.001, respectively.
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our compounds, mainly because their mode of action is different.
All three currently approved drugs affect TG levels by lowering
VLDL synthesis to some extent [48,49], while our compounds
appear to increase the clearance of plasma TG. In support of this we
detected increased LPL activity in homogenates of subcutaneous
white adipose tissue for themost potent compounds at 3 h after the
lipid gavage (preliminary data, not shown).3. Conclusions
Compounds with greater potencies and stability than the
screening hit (1) were designed, synthesized and evaluated in vitro.
The SAR analysis illustrated the necessity of having a carboxylic
acid functional group at the position 5 (or 6) of the bicyclic ring. On
the central phenyl ring, we conﬁrmed the substitution pattern and
evidenced the need of having lipophilic substituents. Larger sub-
stituents at the carbamoyl group were probed as beneﬁcial for the
potency (43). At position 4 of the central fragment, cyclic and more
rigid substituents were not obligatory, and thus, an n-hexylamino
group (60) added a favorable effect. However, the length of the
aliphatic tail was demonstrated as highly important (61 and 62).
Unfortunately, additive effect of favorable modiﬁcations could not
be evidenced. The metabolic stability of the screening hit was also
signiﬁcantly improved by replacing the hydrolysis-prone phthali-
mide scaffold by other heterocyclic fragments. In addition to the
SAR analysis, we challenged previously reported hypotriglyceri-
demic agents in our test system and, consequently, we demon-
strated that our compounds have a different mode of action on LPLactivity than those previously reported. Injections of the optimized
lead compounds (71, 77, 78, 80 and 81) to mice demonstrated that
all compounds lowered plasma TG levels after a lipid gavage
compared to mice treated with vehicle or with the previously
identiﬁed, but unstable, compound 1.
In conclusion, we have developed novel TG lowering com-
pounds that preserve the activity of LPL via a mechanism based
upon stabilization of the dimeric enzyme from inactivation by
ANGPTL4. Preliminary experiments in mice revealed that these
compounds can blunt a postprandial elevation of plasma TG levels
in vivo.4. Experimental section
4.1. General chemical procedures
LCeMS was carried out with a Waters LC system equipped with
an Xterra C18 column (50  19 mm, 5 mm, 125 Å), eluted with a
linear gradient of acetonitrile in water, both of which contained
formic acid (0.2%). A ﬂow rate of 1.5mL/minwas used and detection
was performed at 254 nm. Mass spectra were obtained on a Water
micromass ZQ 2000 using positive and negative electrospray
ionization. 1H NMR and 13C NMR spectra were recorded with a
Bruker DRX-400 or DRX-360 spectrometer. NMR experiments were
conducted at 298 K in DMSO-d6 (residual solvent peak ¼ 2.50 ppm
(dH) and 39.52 (dC)). Compounds 9, 13, 14, 27, 33, 34, 36, 37, 44, 51,
55, 56, 57, 59, 64 and C10 were purchased from ChemBridge Corp.
or Sunblochem HB, analyzed with LCeMS, and used without
further puriﬁcation. All target compounds were 95% pure ac-
cording to HPLC UV-traces, except the low-active compounds 9, 13
and 65 that were 90% pure.4.2. Synthetic procedures
4.2.1. Procedure A: Synthesis of an acyl chloride and coupling to an
aniline derivative (Exempliﬁed by 3)
A catalytic amount of DMF was added to a stirred solution of 2-
chloro-5-nitrobenzoic acid (2) (4.00 g, 19.85 mmol) and oxalyl
chloride (8.65 mL, 99.19 mmol) in DCM (50 mL) at 0 C under ni-
trogen atmosphere. After 20min, the reactionwas allowed towarm
to room temperature and to proceed for a further 2 h. The reaction
mixture was concentrated, re-dissolved in DCM and concentrated
again. Triethylamine (13.83 mL, 99.22 mmol) and p-toluidine
(2.13 g, 19.85 mmol) were added to the crude product dissolved in
DCM (50 mL). The reaction was stirred for 5 h at room temperature
under nitrogen atmosphere. After completion, the reaction mixture
was diluted with DCM and successively washed with HCl (aq., 1 M),
NaHCO3 (aq., sat.), water and brine. The organic phase was dried
overMgSO4, ﬁltered, and concentrated to dryness. The crude amide
was puriﬁed by column chromatography (SiO2, EtOAc/n-heptane,
7:3/ 9:1) to give 3 in 90% yield.
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3-aminobenzoic acid derivatives (Exempliﬁed by 25)
Preparation of the Vilsmeier reagent: oxalyl chloride (404 mL,
4.63 mmol) was added dropwise to a stirred solution of DMF
(358 mL, 4.63 mmol) in DCM (5 mL) at 0 C under nitrogen atmo-
sphere (note: a white foam is forming). The reactionwas allowed to
warm to room temperature and to proceed for 30 min. 3-Amino-5-
bromobenzoic acid (500 mg, 2.31 mmol) in DCM (5 mL) was added
to the Vilsmeier reagent at 0 C and the reactionwas stirred for 1 h.
Pyridine (561 mL, 6.95 mmol) was added to the mixture at 0 C and
the reaction was allowed to warm to room temperature. After
30 min, p-toluidine (248 mg, 2.31 mmol) was added and the re-
action was stirred for a further 2 h. The mixture was then diluted
with DCM and successively washed with NaHCO3, water and brine.
The organic phase was dried over MgSO4 and concentrated to
dryness. The crude amide was puriﬁed by column chromatography
(SiO2, DCM/methanol, 5:1) to give 25 in 60% yield.
4.2.3. Procedure C: Direct amination of aryl chlorides with amino
compounds (Exempliﬁed by 4)
Piperidine (665 mL, 6.72 mmol) and triethylamine (937 mL,
6.72 mmol) were simultaneously added to a stirred solution of 3
(1.70 g, 5.85 mmol) in ethanol (15 mL). The mixture was heated at
reﬂux temperature for 5 h. If the reaction was not completed,
additional amine (e.g. 2 equiv.) was added and the reaction was
allowed to proceed overnight. After completion, the mixture was
slowly cooled to room temperature. The product was ﬁltered off,
washed with cold ethanol and dried under vacuum to give 4 as a
yellow crystalline powder in 94% yield.
4.2.4. Procedure D: Direct amination of aryl bromides with aniline
derivatives (Exempliﬁed by 27)
An oven-dried microwave tube was charged with Pd(OAc)2
(1 mol%, 0.6 mg) and xPhos (3 mol%, 4.0 mg). The vessel was
evacuated and backﬁlled with nitrogen (this process was repeated
3 times). Degassed 1,4-dioxane (0.5 mL) and degassed H2O (4 mol%,
0.2 mL) were successively added and the solution was heated at
80 C for 1.5 min (dark green color). A second oven-dried micro-
wave tube was charged with NaOt-Bu (37.4 mg, 0.39 mmol), 25
(100 mg, 0.28 mmol) and p-toluidine (35.7 mg, 0.33 mmol). The
vessel was evacuated and backﬁlled with nitrogen (this process was
repeated 3 times). The activated catalyst solution was transferred
from the ﬁrst microwave tube into the second one using a degassed
syringe. Additional 1,4-dioxane (0.5 mL) was then added in order to
ease the stirring. The solution was heated at 80e90 C for 5 h. After
completion, the reaction mixture was cooled down to room tem-
perature, diluted with EtOAc, washed with water and brine, dried
over MgSO4 and concentrated to dryness. The crude product was
puriﬁed by column chromatography (SiO2, DCM/methanol, 95:5) to
give 27 in 79% yield.
4.2.5. Procedure E: Direct amination of aryl bromides with
piperidine (Exempliﬁed by 28)
25 (113 mg, 0.31 mmol), copper (I) iodide (5 mol%, 3.18 mg), (R)-
BINOL (20 mol%, 18 mg) and tripotassium phosphate (133.5 mg,
0.63 mmol) were charged in an oven-dried microwave tube. The
vessel was evacuated and backﬁlled with nitrogen (this process was
repeated 3 times) and piperidine (311 mL, 3.15 mmol) was added via
a degassed syringe. The reaction was heated, solvent-free, at 110 C
for 1 day. The crude product was directly used in the next step
(formamidine cleavage) without further puriﬁcation.
4.2.6. Procedure F: Formamidine cleavage (Exempliﬁed by 30)
27 (81 mg, 0.21 mmol) was dissolved in ethanol (5 mL) and
ethylenediamine (63 mL, 0.94 mmol) was added to the mixture. Thereaction was heated at reﬂux temperature for 6 h before being
concentrated. The crude product was puriﬁed by column chroma-
tography (SiO2, EtOAc/n-heptane, 1:1) to give 30 in 93% yield.
4.2.7. Procedure G: O-Alkylation of aryl chlorides and alcohol
(Exempliﬁed by the synthesis of 54)
3 (300 mg, 1.03 mmol) and potassium hydroxide (85.3 mg,
1.55 mmol) were dissolved in DMSO (3 mL) and the mixture was
stirred at room temperature under nitrogen atmosphere. 2-(2-
Methoxyethoxy)ethanol (147 mL, 1.24 mmol) was then added and
the reaction was heated at 60 C for 1 day. After cooling to room
temperature, the reaction mixture was acidiﬁed with HCl (aq., 5%).
The precipitate was ﬁltered off, washed with water and dried under
vacuum to give pure product as a yellow powder in 75% yield.
4.2.8. Procedure H: Reduction of nitro compounds, method 1
(Exempliﬁed by 5)
4 (800 mg, 2.36 mmol) and Pd/C (31 mg) was dissolved/sus-
pended in methanol (20 mL) and stirred vigorously. NaBH4
(222.8 mg, 5.89 mmol) was added portion wise over a period of
30 min and the reactionwas allowed to perform until hydrogen gas
release ended. If the reaction was not completed, additional NaBH4
was added. The solution was ﬁltered through a pad of Celite® and
concentrated. The crude product was puriﬁed by column chroma-
tography (SiO2, EtOAc/n-heptane, 1:9/ 1:1) to give 5 in 90% yield.
4.2.9. Procedure I: Reduction of nitro compounds, method 2
(Exempliﬁed by 5)
SnCl2 (18.07 g, 80.09 mmol) was added to a solution of 4 (5.44 g,
16.05 mmol) in ethanol (100 mL) and the mixture was heated for
3 h at reﬂux temperature. After completion, the reaction mixture
was allowed to cool down to room temperature. The mixture was
then diluted with water and, after removal of the white solid using
a Celite® pad, the product was extracted with ethyl acetate. Pure
product was obtained by crystallization.
4.2.10. Procedure J: Phthalamido compound synthesis by
cyclocondensation of phthalic anhydride derivatives and
amino compounds (Exempliﬁed by 1)
5 (500 mg, 1.62 mmol) and 1,2,4-benzenetricarboxylic anhy-
dride (6, 311 mg, 1.62 mmol) were reﬂuxed in glacial acetic acid
(2.5 mL). After 5 h, the reaction mixture was allowed to cool down
to rt. The product was ﬁltered off, washed abundantly with n-
heptane and dried under vacuum to give 1 as a yellow powder in
89% yield.
4.2.11. Procedure K: Methyl ester synthesis (Exempliﬁed by 12)
1 (50 mg, 0.10 mmol) was dissolved in a DCM/methanol mixture
(1.6:0.2 mL) and the mixture was stirred at room temperature and
under nitrogen atmosphere. Trimethylsilyldiazomethane (2 M in
hexane; 62 mL, 0.12 mmol) was added dropwise over a period of
10 min. After the nitrogen gas release ended, the reaction mixture
was diluted in DCM. The organic phase was successively washed
with NaHCO3, water and brine, dried over MgSO4 and concentrated
to dryness to give 12 as a white powder in 97% yield.
4.2.12. Procedure L: Carboxamide synthesis (Exempliﬁed by 11)
A catalytic amount of DMF was added to a stirred solution of 1
(50 mg, 0.10 mmol) and oxalyl chloride (45 mL, 0.52 mmol) in THF
(1 mL) at 0 C and under nitrogen atmosphere. After 30 min, the
reactionwas allowed to warm to room temperature and to perform
for a further 4 h. Then, the reaction mixture was concentrated,
dissolved in DCM and concentrated again. The crude acyl chloride
was dissolved in DCM (1 mL) and the mixture was stirred at 0 C
and under nitrogen atmosphere. Hexamethyldisilazane (65 mL,
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chloride solution and the reaction was allowed to warm to room
temperature overnight. After removal of the solvent, the crude
product was dissolved in acetone. The remaining solids were
ﬁltered off and the ﬁltrate was concentrated. Recrystallization in
DCM gave 11 in 11% yield.
4.2.13. Procedure M: Cyanation of aryl bromides (Exempliﬁed by
10)
8 (100 mg, 0.19 mmol) and copper (I) cyanide (25.9 mg,
0.29 mmol) were charged in a microwave tube and NMP (0.2 mL)
was added. The vessel was sealed and the reaction, under nitrogen
atmosphere, was heated at 175 C for 20 h. The reaction was
allowed to cool down to room temperature and the mixture was
diluted in ethyl acetate before being ﬁltered through a Celite® pad
and concentrated. The product was puriﬁed on column chroma-
tography (SiO2, EtOAc/n-heptane, 1:5/ 1:0) to give 10 as a white
solid in 29% yield.
4.2.14. Procedure N: Synthesis of amides using phthalic anhydride
derivatives and amino compounds (Exempliﬁed by 65 and 66)
5 (1.1 equiv.) and 1,2,4-benzenetricarboxylic anhydride (6,
29 mg, 0.15 mmol) were stirred in glacial acetic acid (2 mL) for 20 h
at room temperature. After removal of the solvent, 65 and 66 were
separated by reverse phase HPLC (Acetonitrile/Water: 4:6 / 1:1,
with 0.005% of formic acid). The fractions containing pure com-
pound 65 or 66 were combined and lyophilized to give the
regioisomers in 7% and 9% yields, respectively.
4.2.15. Procedure O: Synthesis of aryl bromides via Sandmeyer
reaction (Exempliﬁed by 67)
A concentrated HBr solution (0.5 mL, 8 equiv.) was added
dropwise at 5 C to a suspension of 5 (350 mg, 1.13 mmol) in
acetonitrile (3.5 mL); a pink pale precipitate formed. Then, a cold
aqueous solution of sodium nitrite (1 equiv., 0.35 M) was added
dropwise while the temperature was kept below 5 C. A cold so-
lution of copper (I) bromide (340.6 mg, 2.1 equiv.) in HBr (0.5 mL,
8 equiv.) was added dropwise to the formed diazonium salt. The
reactionwas stirred at room temperature for 1 h and then heated to
reﬂux temperature for an additional hour. The reactionmixturewas
diluted with DCM and washed with brine. The organic phase was
dried over MgSO4, ﬁltered, and concentrated to dryness. The crude
was puriﬁed by column chromatography (SiO2, gradient EtOAc/n-
heptane) to give 67 in 90% yield.
4.2.16. Procedure P: Halogen exchange in aryl halides (Exempliﬁed
by 68)
67 (600 mg, 1.6 mmol), copper (I) iodide (30.6 mg, 0.1 equiv.)
and sodium iodide (482 mg, 2 equiv.) were charged in an oven-
dried microwave tube. The sealed vessel was evacuated and back-
ﬁlled with nitrogen (this process was repeated 3 times) and N,N0-
dimethylethylenediamine (34 mL, 0.2 equiv.) followed by degassed
1,4-dioxane (2.1 mL) were added via a degassed syringe. The re-
action was heated at 110 C for 1 day. After cooling down to room
temperature, the reaction mixture was diluted with DCM and
successively washed with water and brine. The organic phase was
dried over MgSO4, ﬁltered and concentrated to dryness. The crude
was puriﬁed by column chromatography (SiO2, gradient EtOAc/n-
heptane) to give 68 in 94% yield.
4.2.17. Procedure Q: Direct arylation of methyl 1H-benzimidazole-
5-carboxylate (Exempliﬁed by 70)
Methyl 1H-benzimidazole-5-carboxylate (69, 30 mg, 0.17 mmol,
1 equiv.), 68 (143.2 mg, 2 equiv.), copper (I) iodide (65 mg, 2 equiv.),
and palladium (II) acetate (1.9 mg, 0.05 equiv.) were charged in anoven-dried microwave vial. The vessel was evacuated and back-
ﬁlled with nitrogen (this process was repeated 3 times) and dry
DMF (0.8 mL) was added via a degassed syringe. The reaction was
heated at 140 C for 4 days. After cooling down to room tempera-
ture, the reaction mixture was diluted with ethyl acetate and suc-
cessively washed with water and brine. The organic phase was
dried over MgSO4, ﬁltered, and concentrated to dryness. The crude
was puriﬁed by column chromatography (SiO2, DCM/methanol,
95:5) to give 70 in 56% yield.
4.2.18. Procedure R: Methyl ester hydrolysis
An aqueous solution of potassium hydroxide (37 mM) was
added to an ethanolic solution of methyl ester derivative (25 mM).
The reaction mixture was heated to reﬂux temperature for 1 day.
After cooling down to room temperature and the pH of the solution
was set to 2e3 using HCl (aq., 1 M). The precipitate was ﬁltered off,
washed with cold water and dried under vacuum.
4.2.19. Procedure S: Sonogashira coupling reaction of alkyne
derivatives with aryl bromides (Exempliﬁed by 72)
67 (0.11 mmol, 1 equiv.), copper (I) iodide (0.1 equiv.) and bis(-
triphenylphosphine) palladium(II) chloride (0.05 equiv.) were
charged in an oven-dried microwave tube. The vessel was evacu-
ated and backﬁlled with nitrogen (this process was repeated 3
times) and dry DMF (1.2 mL) followed by triethylamine (2.0 equiv.)
were added via a degassed syringe. The reaction was allowed to
perform for 5 min at room temperature and trimethylsilylacetylene
(3.0 equiv.) was added. The reaction was heated at 60 C for 2 days.
After cooling down to room temperature, the reaction mixture was
diluted with ethyl acetate and washed with brine. The organic
phase was dried over MgSO4, ﬁltered, and concentrated to dryness.
The crude was dissolved in a methanol/THF mixture (1:4) and po-
tassium carbonate (2 equiv.) was added. After overnight stirring,
the reaction mixture was diluted with ethyl acetate and washed
with brine. The organic phase was dried over MgSO4, ﬁltered, and
concentrated to dryness. The crude was puriﬁed by column chro-
matography to yield 72 in 60% yield.
4.2.20. Procedure T: Synthesis of benzofuran and indole derivatives
via Sonogashira coupling reaction of alkyne with aryl iodides
(Exempliﬁed by 72)
73 (0.11 mmol, 1 equiv.), 72 (2 equiv.), copper (I) iodide
(0.1 equiv.) and bis(triphenylphosphine) palladium(II) chloride
(0.05 equiv.) were charged in an oven-dried microwave tube. The
vessel was evacuated and backﬁlled with nitrogen (this process was
repeated 3 times) and dry DMF (1.2 mL) followed by triethylamine
(2.7 equiv.) were added via a degassed syringe. The reaction was
heated under microwave irradiation conditions at 110 C for
20 min. After cooling to room temperature, the reaction mixture
was diluted with ethyl acetate and washed with brine. The organic
phase was dried over MgSO4, ﬁltered, and concentrated to dryness.
The crude was puriﬁed by column chromatography to give 75 in
67% yield.
4.2.21. Procedure U: Synthesis of 2H-indazole derivatives
(Exempliﬁed by 80)
5 (3 mmol, 1 equiv.) and 79 (1 equiv.) were dissolved in ethanol
(70 mL) and the mixture was reﬂuxed for 20 min. After cooling
down to room temperature, the formed precipitate was ﬁltered off,
washed carefully with cold ethanol and dried under vacuum. The
preformed imine (1.77 mmol, 1 equiv.) and cesium carbonate
(1.0 equiv.) were dissolved in dry, degassed DMSO (80 mL) and the
mixture was heated at 100 C. A freshly prepared DMSO solution
(4 mL) of copper iodide (0.2 equiv.) and TMEDA (0.2 equiv.) was
added to the reaction vessel. Sodium azide (2.0 equiv.) was then
R. Caraballo et al. / European Journal of Medicinal Chemistry 103 (2015) 191e209202added in small portions and the reaction was stirred at 120 C for
24 h. The brown mixture was allowed to reach room temperature,
diluted in ethyl acetate and successively washed with HCl (1 M),
brine, dried over Na2SO4, ﬁltered and concentrated to give a brown
solid. The crude solid was triturated with ethanol and then ethanol
was pipetted off. The solids were dissolved in 50 mL of hot ethanol
and the product was precipitated with 200 mL of heptane. After
cooling to ca. 10 C, the solids were vacuum ﬁltered to give 80 in
56% yield. (Note: The reaction proved more efﬁcient when the
imine was preformed. A one-pot procedure where all the reactants
were added together also provided the desire product, albeit a
lower reaction efﬁciency.)
4.3. Tabulated compounds
4.3.1. 1,3-Dioxo-2-(4-(piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)
isoindoline-5-carboxylic acid (1)
1 was synthesized by procedures A, C, H (or I) and J.
1H NMR (400MHz, DMSO-d6): d 13.80 (bs, 1H), 11.43 (s, 1H), 8.41
(dd, J ¼ 1.5, 7.7 Hz, 1H), 8.30 (d, J ¼ 1.4 Hz, 1H), 8.05 (d, J ¼ 7.7 Hz,
1H), 7.88 (d, J ¼ 2.6 Hz, 1H), 7.66 (d, J ¼ 8.3 Hz, 2H), 7.56 (dd, J ¼ 2.6,
8.5 Hz,1H), 7.43 (d, J¼ 8.7 Hz,1H), 7.18 (d, J¼ 8.6 Hz, 2H), 2.95e3.05
(m, 4H), 2.28 (s, 3H), 1.62e1.73 (m, 4H), 1.48e1.58 (m, 2H).
13C NMR (100.5 MHz, DMSO-d6): d 166.36, 166.35, 165.84,
163.92, 151.41, 136.40, 136.36, 135.41, 135.03, 132.49, 132.16, 130.57,
129.38, 129.07, 126.81, 123.77, 123.33, 120.80, 119.32, 53.70, 25.95,
23.29, 20.50.
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
484.21.
4.3.2. 5-(1,3-Dioxoisoindolin-2-yl)-2-(piperidin-1-yl)-N-p-
tolylbenzamide (7)
7 was synthesized by procedures A, C, H and J.
1H NMR (400MHz, DMSO-d6): d 11.46 (s,1H), 7.94e8.00 (m, 2H),
7.88e7.94 (m, 2H), 7.86 (d, J ¼ 2.5 Hz, 1H), 7.66 (d, J ¼ 8.3 Hz, 2H),
7.55 (dd, J ¼ 2.6, 8.5 Hz, 1H), 7.43 (d, J ¼ 8.6 Hz, 1H), 7.18 (d,
J ¼ 8.4 Hz, 2H), 2.95e3.07 (m, 4H), 2.28 (s, 3H), 1.62e1.74 (m, 4H),
1.48e1.59 (m, 2H).
ESI-MS m/z calcd for C27H25N3O3 (M þ H)þ 440.19; found:
439.97.
4.3.3. 5-(5-Bromo-1,3-dioxoisoindolin-2-yl)-2-(piperidin-1-yl)-N-
p-tolylbenzamide (8)
8 was synthesized by procedures A, C, H and J.
1H NMR (360 MHz, DMSO-d6): d 11.43 (s, 1H), 8.17 (d, J ¼ 1.8 Hz,
1H), 8.1 (dd, J ¼ 1.8, 7.9 Hz, 1H), 7.9 (d, J ¼ 7.9 Hz, 1H), 7.85 (d,
J ¼ 2.5 Hz, 1H), 7.66 (d, J ¼ 8.1 Hz, 2H), 7.54 (dd, J ¼ 2.7, 8.4 Hz, 1H),
7.43 (d, J¼ 8.7 Hz,1H), 7.18 (d, J¼ 8.4 Hz, 2H), 3.01 (t, J¼ 4.8 Hz, 4H),
2.28 (s, 3H), 1.61e1.73 (m, 4H), 1.48e1.58 (m, 2H).
ESI-MS m/z calcd for C27H24BrN3O3 (M þ H)þ 518.10; found:
518.11.
4.3.4. 5-(5-Amino-1,3-dioxoisoindolin-2-yl)-2-(piperidin-1-yl)-N-
p-tolylbenzamide (9)
1H NMR (400 MHz, DMSO-d6): d 11.53 (s, 1H), 7.80 (d, J ¼ 2.6 Hz,
1H), 7.65 (d, J ¼ 8.4 Hz, 2H), 7.58 (d, J ¼ 8.3 Hz, 1H), 7.50 (dd, J ¼ 2.6,
8.5 Hz, 1H), 7.40 (d, J ¼ 8.7 Hz, 1H), 7.18 (d, J ¼ 8.3 Hz, 2H), 7.00 (d,
J¼ 2.0 Hz,1H), 6.86 (dd, J¼ 2.0, 8.3 Hz,1H), 6.56 (bs, 2H), 2.95e3.03
(m, 4H), 2.28 (s, 3H), 1.62e1.74 (m, 4H), 1.49e1.58 (m, 2H).
ESI-MS m/z calcd for C27H26N4O3 (M þ H)þ 455.20; found:
455.02.
4.3.5. 5-(5-Cyano-1,3-dioxoisoindolin-2-yl)-2-(piperidin-1-yl)-N-
p-tolylbenzamide (10)
10 was synthesized by procedure M.1H NMR (400 MHz, DMSO-d6): d 11.41 (s, 1H), 8.51 (s, 1H), 8.37
(dd, J ¼ 1.4, 7.7 Hz, 1H), 8.14 (d, J ¼ 7.8 Hz, 1H), 7.87 (d, J ¼ 2.6 Hz,
1H), 7.65 (d, J ¼ 8.1 Hz, 2H), 7.55 (dd, J ¼ 2.6, 8.5 Hz, 1H), 7.44 (d,
J ¼ 8.6 Hz, 1H), 7.18 (d, J ¼ 8.1 Hz, 2H), 2.98e3.05 (m, 4H), 2.28 (s,
3H), 1.63e1.72 (m, 4H), 1.50e1.58 (m, 2H).
ESI-MS m/z calcd for C28H24N4O3 (M þ H)þ 465.18; found:
465.38.
4.3.6. 1,3-Dioxo-2-(4-(piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)
isoindoline-5-carboxamide (11)
11 was synthesized by procedure L.
1H NMR (360MHz, DMSO-d6): d 11.44 (s,1H), 8.33e8.43 (m, 3H),
8.05 (d, J ¼ 7.8 Hz, 1H), 7.87 (d, J ¼ 2.6 Hz, 1H), 7.79 (bs, 1H), 7.66 (d,
J ¼ 8.3 Hz, 2H), 7.56 (dd, J ¼ 2.7, 8.6 Hz, 1H), 7.43 (d, J ¼ 8.7 Hz, 1H),
7.18 (d, J¼ 8.7 Hz, 2H), 2.98e3.04 (m, 4H), 2.28 (s, 3H),1.64e1.72 (m,
4H), 1.50e1.58 (m, 2H).
ESI-MS m/z calcd for C28H26N4O4 (M þ H)þ 483.20; found:
483.27.
4.3.7. Methyl-1,3-dioxo-2-(4-(piperidin-1-yl)-3-(p-tolylcarbamoyl)
phenyl)isoindoline-5-carboxylate (12)
12 was synthesized by procedure K.
1H NMR (360MHz, DMSO-d6): d 11.42 (bs,1H), 8.43 (d, J¼ 7.8 Hz,
1H), 8.32 (s, 1H), 8.33 (s, 1H), 8.11 (d, J ¼ 7.8 Hz, 1H), 7.88 (d,
J ¼ 2.5 Hz, 1H), 7.66 (d, J ¼ 8.1 Hz, 2H), 7.56 (dd, J ¼ 2.5, 8.5 Hz, 1H),
7.43 (d, J¼ 8.6 Hz,1H), 7.18 (d, J¼ 8.1 Hz, 2H), 3.95 (s, 3H), 2.97e3,05
(m, 4H), 2.28 (s, 3H), 1.62e1.72 (m, 4H), 1.49e1.58 (m, 2H).
ESI-MS m/z calcd for C29H27N3O5 (M þ H)þ 498.20; found:
498.07.
4.3.8. 1,3-Dioxo-2-(4-(piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)
isoindoline-4-carboxylic acid (13)
1H NMR (400 MHz, DMSO-d6): d 13.69 (bs, 1H), 11.43 (s, 1H),
7.90e8.10 (m, 3H), 7.85 (d, J ¼ 2.6 Hz, 1H), 7.66 (d, J ¼ 8.3 Hz, 2H),
7.55 (dd, J ¼ 2.6, 8.6 Hz, 1H), 7.42 (d, J ¼ 8.6 Hz, 1H), 7.18 (d,
J ¼ 8.6 Hz, 2H), 2.98e3.06 (m, 4H), 2.28 (s, 3H), 1.63e1.72 (m, 4H),
1.49e1.59 (m, 2H).
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
483.97.
4.3.9. 2-(3-Chloro-5-(p-tolylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (14)
1H NMR (400MHz, DMSO-d6): d 13.80 (bs,1H),10.37 (s,1H), 8.44
(dd, J ¼ 1.4, 7.8 Hz, 1H), 8.34 (s, 1H), 8.15 (t, J ¼ 2.22 Hz, 1H), 8.13 (d,
J¼ 7.7 Hz, 1H), 8.02 (t, J ¼ 1.7 Hz, 1H), 7.82 (t, J¼ 1.9 Hz, 1H), 7.64 (d,
J ¼ 8.5 Hz, 2H), 7.16 (d, J ¼ 8.7 Hz, 2H), 2.29 (s, 3H).
ESI-MS m/z calcd for C23H15ClN2O5 (M þ H)þ 435.07; found:
434.90.
4.3.10. 1,3-Dioxo-2-(3-(phenylamino)-5-(p-tolylcarbamoyl)phenyl)
isoindoline-5-carboxylic acid (15)
15 was synthesized by procedures B, D, F and J.
1H NMR (360MHz, DMSO-d6): d 13.76 (bs,1H),10.20 (s, 1H), 8.64
(s, 1H), 8.42 (dd, J ¼ 1.1, 7.4 Hz, 1H), 8.32 (s, 1H), 8.09 (d, J ¼ 7.8 Hz,
1H), 7.63 (m, 3H), 7.42 (t, J ¼ 1.5 Hz, 1H), 7.37 (t, J ¼ 1.5 Hz, 1H), 7.29
(t, J ¼ 7.48 Hz, 2H), 7.19 (d, J ¼ 8.3 Hz, 2H), 7.15 (d, J ¼ 8.3 Hz, 2H),
6.91 (t, J ¼ 7.3 Hz, 1H), 2.28 (s, 3H).
ESI-MS m/z calcd for C29H21N3O5 (M þ H)þ 492.15; found:
492.28.
4.3.11. 1,3-Dioxo-2-(3-(p-tolylamino)-5-(p-tolylcarbamoyl)phenyl)
isoindoline-5-carboxylic acid (16)
16 was synthesized by procedures B, D, F and J.
1H NMR (360MHz, DMSO-d6): d 13.02 (bs, 1H), 10.18 (s, 1H), 8.49
(s, 1H), 8.42 (d, J ¼ 7.8 Hz, 1H), 8.32 (s, 1H), 8.08 (d, J ¼ 7.8 Hz, 1H),
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1H), 7.06e7.17 (m, 6H), 2.27 (s, 3H), 2.24 (s, 3H).
ESI-MS m/z calcd for C30H23N3O5 (M þ H)þ 506.16; found:
505.82.
4.3.12. 1,3-Dioxo-2-(5-(piperidin-1-yl)-2-(p-tolylcarbamoyl)
phenyl)isoindoline-5-carboxylic acid (17)
17 was synthesized by procedures A, C, I and J.
1H NMR (400MHz, DMSO-d6): d 13.72 (bs,1H),10.33 (s,1H), 8.39
(dd, J ¼ 1.5, 7.7 Hz, 1H), 8.26 (s, 1H), 8.03 (d, J ¼ 7.7 Hz, 1H), 7.44 (d,
J ¼ 8.3 Hz, 2H), 7.31 (d, J ¼ 8.8 Hz, 1H), 7.25 (d, J ¼ 2.7 Hz, 1H), 7.19
(dd, J ¼ 2.5, 8.4 Hz, 1H), 7.06 (d, J ¼ 8.0 Hz, 2H), 3.28e3.38 (m, 4H),
2.22 (s, 3H), 1.54e1.71 (m, 6H).
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
484.04.
4.3.13. 1,3-Dioxo-2-(2-(piperidin-1-yl)-6-(p-tolylcarbamoyl)
phenyl)isoindoline-5-carboxylic acid (18)
18 was synthesized by procedures A, C, I and J.
1H NMR (400MHz, DMSO-d6): d 13.71 (bs,1H),10.38 (s, 1H), 8.41
(d, J ¼ 7.6 Hz, 1H), 8.30 (s, 1H), 8.06 (d, J ¼ 7.8 Hz, 1H), 7.60 (t,
J¼ 7.9 Hz, 1H), 7.40e7.51 (m, 4H), 7.06 (d, J¼ 8.0 Hz, 2H), 2.69e2.78
(m, 4H), 2.22 (s, 3H), 1.24e1.41 (m, 6H).
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
483.93.
4.3.14. 1,3-Dioxo-2-(4-(piperidin-1-yl)-2-(p-tolylcarbamoyl)
phenyl)isoindoline-5-carboxylic acid (19)
1H NMR (400MHz, DMSO-d6): d 13.65 (bs,1H),10.33 (s,1H), 8.38
(dd, J ¼ 1.0, 7.7 Hz, 1H), 8.25 (s, 1H), 8.01 (d, J ¼ 7.7 Hz, 1H), 7.44 (d,
J ¼ 8.3 Hz, 2H), 7.31 (d, J ¼ 8.9 Hz, 1H), 7.25 (d, J ¼ 2.7 Hz, 1H), 7.19
(dd, J ¼ 2.7, 8.8 Hz, 1H), 7.06 (d, J ¼ 8.4 Hz, 2H), 3.30e3.40 (m, 4H),
2.22 (s, 3H), 1.55e1.73 (m, 6H).
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
483.97.
4.3.15. 1,3-Dioxo-2-(2-(piperidin-1-yl)-5-(p-tolylcarbamoyl)
phenyl)isoindoline-5-carboxylic acid (20)
20 was synthesized by procedures A, C, I and J.
1H NMR (400MHz, DMSO-d6): d 13.79 (bs, 1H), 11.21 (s, 1H), 8.43
(dd, J ¼ 1.5, 7.8 Hz, 1H), 8.32 (s, 1H), 8.09 (d, J ¼ 7.8 Hz, 1H), 7.87 (d,
J ¼ 8.2 Hz, 1H), 7.67 (d, J ¼ 8.4 Hz, 2H), 7.38 (d, J ¼ 2.0 Hz, 1H), 7.26
(dd, J ¼ 1.8, 8.4 Hz, 1H), 7.18 (d, J ¼ 8.5 Hz, 2H), 2.93e3.03 (m, 4H),
2.29 (s, 3H), 1.60e1.71 (m, 4H), 1.45e1.55 (m, 2H).
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
483.97.
4.3.16. 1,3-Dioxo-2-(3-(piperidin-1-yl)-4-(p-tolylcarbamoyl)
phenyl)isoindoline-5-carboxylic acid (21)
21 was synthesized by procedures A, C, I and J.
1H NMR (400MHz, DMSO-d6): d 13.79 (bs, 1H),10.10 (s, 1H), 8.45
(dd, J ¼ 1.4, 7.7 Hz, 1H), 8.36 (s, 1H), 8.14 (d, J ¼ 7.8 Hz, 1H), 8.06 (dd,
J ¼ 2.3, 8.5 Hz, 1H), 7.94 (d, J ¼ 2.2 Hz, 1H), 7.63 (d, J ¼ 8.4 Hz, 2H),
7.33 (d, J ¼ 8.5 Hz, 1H), 7.15 (d, J ¼ 8.6 Hz, 2H), 2.75e2.88 (m, 4H),
2.27 (s, 3H), 1.26e1.43 (m, 6H).
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
483.97.
4.3.17. 1,3-Dioxo-2-(2-(piperidin-1-yl)-3-(p-tolylcarbamoyl)
phenyl)isoindoline-5-carboxylic acid (22)
22 was synthesized by procedures A, C, I and J.
1H NMR (400MHz, DMSO-d6): d 13.79 (bs,1H),10.45 (s,1H), 8.46
(dd, J ¼ 1.5, 7.7 Hz, 1H), 8.36 (s, 1H), 8.14 (d, J ¼ 7.8 Hz, 1H), 7.63 (d,
J ¼ 8.4 Hz, 2H), 7.46e7.54 (m, 2H), 7.31 (7, J ¼ 7.7 Hz, 1H), 7.14 (d,
J ¼ 8.5 Hz, 2H), 2.76e2.90 (m, 4H), 2.27 (s, 3H), 1.06e1.28 (m, 6H).ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
484.02.
4.3.18. 1,3-Dioxo-2-(3-(piperidin-1-yl)-5-(p-tolylcarbamoyl)
phenyl)isoindoline-5-carboxylic acid (23)
23 was synthesized by procedures B, E, F and J.
1H NMR (400MHz, DMSO-d6): d 13.75 (bs,1H), 10.15 (s, 1H), 8.43
(dd, J ¼ 1.5, 7.8 Hz, 1H), 8.32 (s, 1H), 8.09 (d, J ¼ 7.8 Hz, 1H), 7.62 (d,
J ¼ 8.4 Hz, 2H), 7.52 (t, J ¼ 1.6 Hz, 1H), 7.33 (t, J ¼ 1.8 Hz, 1H), 7.21 (t,
J ¼ 2.2 Hz, 1H), 7.16 (d, J ¼ 8.8 Hz, 2H), 3.25e3.31 (m, 4H), 2.28 (s,
3H), 1.62e1.68 (m, 4H), 1.54e1.62 (m, 2H).
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
484.21.
4.3.19. 2-Phenylisoindoline-1,3-dione (31)
31 was synthesized by procedure J.
1H NMR (400 MHz, DMSO-d6): d 7.88e8.02 (m, 4H), 7.40e7.57
(m, 5H).
ESI-MSm/z calcd for C14H9NO2 (M þ H)þ 224.06; found: 224.19.
4.3.20. 1,3-Dioxo-2-phenylisoindoline-5-carboxylic acid (32)
32 was synthesized by procedure J.
1H NMR (400 MHz, DMSO-d6): d 13.76 (bs, 1H), 8.41 (dd, J ¼ 1.4,
7.7 Hz, 1H), 8.31 (s, 1H), 8.09 (d, J ¼ 7.7 Hz, 1H), 7.42e7.59 (m, 5H).
ESI-MSm/z calcd for C15H9NO4 (M  H) 266.05; found: 266.02.
4.3.21. 1,3-Dioxo-2-(3-(phenylcarbamoyl)-4-(piperidin-1-yl)
phenyl)isoindoline-5-carboxylic acid (33)
1H NMR (400MHz, DMSO-d6): d 13.77 (bs, 1H), 11.54 (s, 1H), 8.41
(dd, J ¼ 1.5, 7.7 Hz, 1H), 8.30 (s, 1H), 8.07 (d, J ¼ 7.8 Hz, 1H), 7.90 (d,
J ¼ 2.6 Hz, 1H), 7.78 (d, J ¼ 7.7 Hz, 2H), 7.57 (dd, J ¼ 2.5, 8.5 Hz, 1H),
7.44 (d, J ¼ 8.8 Hz, 1H), 7.38 (dd, J ¼ 7.5, 8.5 Hz, 2H), 7.10 (dd, J ¼ 7.0,
7.7 Hz,1H), 2.96e3.09 (m, 4H), 2.58 (q, J¼ 7.6 Hz, 2H), 1.62e1.74 (m,
4H), 1.49e1.60 (m, 2H), 1.18 (t, J ¼ 7.6 Hz, 3H).
ESI-MS m/z calcd for C27H23N3O5 (M þ H)þ 470.16; found:
469.98.
4.3.22. 2-(3-(4-Methoxyphenylcarbamoyl)-4-(piperidin-1-yl)
phenyl)-1,3-dioxoisoindoline-5-carboxylic acid (34)
1H NMR (400MHz, DMSO-d6): d 13.73 (bs, 1H), 11.40 (s, 1H), 8.41
(dd, J ¼ 1.4, 7.8 Hz, 1H), 8.30 (s, 1H), 8.08 (d, J ¼ 7.7 Hz, 1H), 7.88 (d,
J ¼ 2.4 Hz, 1H), 7.69 (d, J ¼ 8.6 Hz, 2H), 7.56 (dd, J ¼ 2.5, 8.6 Hz, 1H),
7.43 (d, J ¼ 8.6 Hz, 1H), 6.96 (d, J ¼ 8.6 Hz, 2H), 3.75 (s, 3H),
2.93e3.07 (m, 4H), 1.61e1.74 (m, 4H), 1.49e1.58 (m, 2H).
ESI-MS m/z calcd for C28H25N3O6 (M þ H)þ 500.17; found:
499.90.
4.3.23. 1,3-Dioxo-2-(4-(piperidin-1-yl)-3-(4-(triﬂuoromethyl)
phenylcarbamoyl)phenyl)isoindoline-5-carboxylic acid (35)
35 was synthesized by procedures A, C, H and J.
1H NMR (400 MHz, DMSO-d6): d 13.75 (bs, 1H); 11.66 (s, 1H);
8.42 (dd, J¼ 1.3, 7.8 Hz,1H); 8.31 (s,1H); 8.08 (d, J¼ 7.7 Hz,1H); 7.99
(d, J ¼ 8.5 Hz, 2H); 7.85 (d, J ¼ 2.5 Hz, 1H); 7.76 (d, J ¼ 8.7 Hz, 2H);
7.59 (dd, J ¼ 2.5, 8.7 Hz, 1H); 7.44 (d, J ¼ 8.6 Hz, 1H); 3.03 (t,
J ¼ 4.6 Hz, 4H); 1.61e1.70 (m, 4H); 1.49e1.57 (m, 2H).
ESI-MS m/z calcd for C28H22F3N3O5 (M þ H)þ 538.15; found:
538.21.
4.3.24. 1,3-Dioxo-2-(4-(piperidin-1-yl)-3-(m-tolylcarbamoyl)
phenyl)isoindoline-5-carboxylic acid (36)
1H NMR (400MHz, DMSO-d6): d 13.74 (bs, 1H), 11.44 (s, 1H), 8.42
(dd, J ¼ 1.5, 7.7 Hz, 1H), 8.31 (s, 1H), 8.08 (d, J ¼ 7.7 Hz, 1H), 7.87 (d,
J ¼ 2.6 Hz, 1H), 7.66 (s, 1H), 7.57 (dd, J ¼ 2.6, 8.6 Hz, 1H), 7.50 (d,
J¼ 7.6 Hz,1H), 7.44 (d, J¼ 8.7 Hz,1H), 7.26 (t, J¼ 7.8 Hz,1H), 6.93 (d,
J ¼ 7.4 Hz, 1H), 2.97e3.07 (m, 4H), 2.32 (s, 3H), 1.61e1.74 (m, 4H),
R. Caraballo et al. / European Journal of Medicinal Chemistry 103 (2015) 191e2092041.49e1.60 (m, 2H).
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
483.93.
4.3.25. 2-(3-(4-Ethylphenylcarbamoyl)-4-(piperidin-1-yl)phenyl)-
1,3-dioxoisoindoline-5-carboxylic acid (37)
1H NMR (400 MHz, DMSO-d6): d 13.76 (bs, 1H), 11.47 (s, 1H), 8.41
(dd, J ¼ 1.4, 7.8 Hz, 1H), 8.30 (s, 1H), 8.08 (d, J ¼ 7.7 Hz, 1H), 7.88 (d,
J ¼ 2.5 Hz, 1H), 7.68 (d, J ¼ 8.1 Hz, 2H), 7.56 (dd, J ¼ 2.5, 8.5 Hz, 1H),
7.44 (d, J ¼ 8.7 Hz, 1H), 7.22 (d, J ¼ 8.1 Hz, 2H), 2.96e3.07 (m, 4H),
2.58 (q, J ¼ 7.6 Hz, 2H), 1.62e1.74 (m, 4H), 1.48e1.59 (m, 2H), 1.18 (t,
J ¼ 7.6 Hz, 3H).
ESI-MS m/z calcd for C29H27N3O5 (M þ H)þ 498.20; found:
497.99.
4.3.26. 2-(3-(Biphenyl-2-ylcarbamoyl)-4-(phenylamino)phenyl)-
1,3-dioxoisoindoline-5-carboxylic acid (38)
38 was synthesized by procedures A, C, H and J.
1H NMR (360MHz, DMSO-d6): d 13.81 (bs, 1H), 10.02 (s, 1H), 9.13
(s, 1H), 8.43 (dd, J ¼ 1.6, 7.7 Hz, 1H), 8.34 (s, 1H), 8.11 (d, J ¼ 7.8 Hz,
1H), 7.7 (d, J ¼ 2.3 Hz, 1H), 7.55 (d, J ¼ 7.6 Hz, 1H), 7.27e7.44 (m,
11H), 7.2 (t, J ¼ 6.9 Hz, 1H), 7.13 (d, J ¼ 7.7 Hz, 2H), 7.02 (t, J ¼ 7.3 Hz,
1H).
13C NMR (100.5 MHz, DMSO-d6): d 166.84, 166.48, 166.46,
165.83, 144.00, 141.15, 138.99, 137.87, 136.61, 135.62, 134.77, 134.47,
131.92, 131.22, 130.22, 129.43, 128.48, 128.34, 128.28, 127.86, 127.57,
127.11, 126.73, 123.87, 123.41, 122.31, 121.96, 119.85, 115.73.
ESI-MS m/z calcd for C34H23N3O5 (M  H) 552.16; found:
552.26.
4.3.27. 2-(3-(4-Isopropylphenylcarbamoyl)-4-(piperidin-1-yl)
phenyl)-1,3-dioxoisoindoline-5-carboxylic acid (39)
39 was synthesized by procedures A, C, H and J.
1H NMR (400MHz, DMSO-d6): d 13.75 (bs, 1H), 11.51 (s, 1H), 8.42
(dd, J¼ 1.5, 7.8 Hz, 1H), 8.31 (s, 1H), 8.08 (d, J ¼ 7.8 Hz, 1H), 7.89 (dd,
J ¼ 2.4, 3.2 Hz, 1H), 7.68 (d, J ¼ 8.7 Hz, 2H), 7.57 (dd, J ¼ 2.6, 8.5 Hz,
1H), 7.45 (dd, J ¼ 2.7, 8.8 Hz, 1H), 7.25 (d, J ¼ 8.5 Hz, 2H), 2.98e3.06
(m, 4H), 2.87 (hept, J ¼ 6.9 Hz, 1H), 1.64e1.74 (m, 4H), 1.51e1.60 (m,
2H), 1.21 (d, J ¼ 6.9 Hz, 6H).
13C NMR (100.5 MHz, DMSO-d6): d 166.35, 165.83, 163.83, 151.41,
143.60, 136.60, 136.36, 135.40, 135.02, 132.15, 130.59, 129.09, 129.01,
126.89, 126.71, 123.76, 123.31, 120.91, 119.46, 53.72, 25.96, 23.95,
23.27.
ESI-MS m/z calcd for C30H29N3O5 (M þ H)þ 512.21; found:
512.31.
4.3.28. 2-(3-(3-Ethylphenylcarbamoyl)-4-(piperidin-1-yl)phenyl)-
1,3-dioxoisoindoline-5-carboxylic acid (40)
40 was synthesized by procedures A, C, H and J.
1H NMR (400MHz, DMSO-d6): d 13.74 (bs, 1H), 11.53 (s, 1H), 8.42
(dd, J¼ 1.5, 7.8 Hz, 1H), 8.31 (s, 1H), 8.08 (d, J ¼ 7.8 Hz, 1H), 7.89 (dd,
J¼ 2.4, 3.2 Hz,1H), 7.66 (s, 1H), 7.57 (dt, J¼ 2.5, 8.5 Hz, 2H), 7.45 (dd,
J ¼ 2.9, 8.7 Hz, 1H), 7.28 (t, J ¼ 7.8 Hz, 1H), 6.96 (d, J ¼ 7.59 Hz, 1H),
2.97e3.10 (m, 4H), 2.62 (q, J ¼ 7.5 Hz, 2H), 1.64e1.76 (m, 4H),
1.50e1.60 (m, 2H), 1.20 (t, J ¼ 7.6 Hz, 3H).
13C NMR (100.5 MHz, DMSO-d6): d 166.36, 165.85, 164.01, 151.46,
144.53, 138.89, 136.44, 135.43, 135.01, 132.15, 130.64, 129.07, 129.00,
128.91, 126.93, 123.79, 123.34, 123.11, 120.96, 118.71, 116.84, 53.75,
28.28, 25.96, 23.29, 15.48.
ESI-MS m/z calcd for C29H27N3O5 (M þ H)þ 498.20; found:
498.26.
4.3.29. 2-(3-(4-Ethylphenylcarbamoyl)-4-(phenylamino)phenyl)-
1,3-dioxoisoindoline-5-carboxylic acid (41)
41 was synthesized by procedures A, C, H and J.1H NMR (400MHz, DMSO-d6): d 13.77 (bs,1H),10.30 (s,1H), 9.24
(s, 1H), 8.43 (dd, J ¼ 1.5, 7.7 Hz, 1H), 8.33 (s, 1H), 8.10 (d, J ¼ 7.8 Hz,
1H), 7.81 (d, J ¼ 2.2 Hz, 1H), 7.59 (d, J ¼ 8.4 Hz, 2H), 7.39e7.47 (m,
2H), 7.30e7.37 (m, 2H), 7.23 (dd, J ¼ 1.1, 8.6 Hz, 2H), 7.17 (d,
J¼ 8.3 Hz, 2H), 7.01 (t, J¼ 7.5 Hz, 1H), 2.57 (q, J ¼ 7.6 Hz, 2H), 1.16 (t,
J ¼ 7.6 Hz, 3H).
13C NMR (100.5 MHz, DMSO-d6): d 166.57, 166.54, 165.83,
144.05, 141.20, 139.44, 136.61, 136.29, 136.00, 134.80, 131.96, 131.24,
129.46, 128.41, 127.80, 123.85, 123.39, 122.33, 121.92, 120.77, 120.51,
119.96, 115.76, 27.67, 15.71.
ESI-MS m/z calcd for C30H23N3O5 (M þ H)þ 506.16; found:
506.20.4.3.30. 2-(3-(4-Isopropylphenylcarbamoyl)-4-(phenylamino)
phenyl)-1,3-dioxoisoindoline-5-carboxylic acid (42)
42 was synthesized by A, C, H and J.
1H NMR (400MHz, DMSO-d6): d 13.77 (bs,1H),10.30 (s,1H), 9.24
(s, 1H), 8.43 (dd, J ¼ 1.5, 7.7 Hz, 1H), 8.33 (s, 1H), 8.10 (d, J ¼ 7.7 Hz,
1H), 7.81 (d, J ¼ 2.2 Hz, 1H), 7.59 (d, J ¼ 8.5 Hz, 2H), 7.39e7.48 (m,
2H), 7.34 (t, J ¼ 7.4 Hz, 2H), 7.23 (dd, J ¼ 1.0, 8.6 Hz, 2H), 7.21 (d,
J¼ 8.6 Hz, 2H), 7.02 (t, J¼ 7.3 Hz,1H), 2.86 (hept, J¼ 6.9 Hz,1H), 1.19
(d, J ¼ 6.9 Hz, 6H).
13C NMR (100.5 MHz, DMSO-d6): d 166.53, 165.82, 144.08,
144.04, 141.19, 136.67, 136.36, 135.58, 134.76, 131.94, 131.22, 129.44,
128.39, 126.29, 123.82, 123.38, 122.31, 121.91, 120.78, 120.49, 119.95,
115.73, 32.91, 23.94.
ESI-MS m/z calcd for C31H25N3O5 (M þ H)þ 520.18; found:
520.31.4.3.31. 2-(3-(Biphenyl-2-ylcarbamoyl)-4-(piperidin-1-yl)phenyl)-
1,3-dioxoisoindoline-5-carboxylic acid (43)
43 was synthesized by procedures A, C, H and J.
1H NMR (360MHz, DMSO-d6): d 11.56 (bs,1H), 8.42 (d, J¼ 7.8 Hz,
1H), 8.32 (s, 1H), 8.25 (d, J¼ 8.3 Hz,1H), 8.13e8.08 (m, 2H), 7.59 (dd,
J¼ 8.6, 2.7 Hz,1H), 7.47 (d, J¼ 4.7 Hz, 4H), 7.45e7.36 (m, 4H), 7.29 (t,
J ¼ 7.5 Hz, 1H), 2.70 (m, 4H), 1.25 (m, 2H), 1.02 (m, 4H).
13C NMR (100.5 MHz, DMSO-d6): d 166.34, 165.83,163.38, 151.77,
138.42, 136.38, 135.43, 135.03, 134.67, 132.91, 132.16, 131.22, 130.67,
129.65, 129.01, 128.94, 128.03, 127.79, 127.70, 127.59, 125.08, 123.82,
123.35, 121.34, 54.18, 24.94, 22.71, 21.06.
ESI-MS m/z calcd for C33H27N3O5 (M þ H)þ 546.20; found:
546.46.4.3.32. 2-(3-(Benzylcarbamoyl)-4-(piperidin-1-yl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (44)
1H NMR (400MHz, DMSO-d6): d 13.77 (bs,1H), 9.99 (t, J¼ 5.8 Hz,
1H), 8.41 (d, J ¼ 7.8 Hz, 1H), 8.30 (s, 1H), 8.08 (d, J ¼ 7.8 Hz, 1H), 7.89
(d, J ¼ 2.4 Hz, 1H), 7.52 (dd, J ¼ 2.5, 8.4 Hz, 1H), 7.24e7.44 (m, 6H),
4.54 (d, J ¼ 5.7 Hz, 2H), 2.84e2.93 (m, 4H), 1.34e1.52 (m, 6H).
ESI-MS m/z calcd for C28H25N3O5 (M þ H)þ 484.18; found:
483.94.4.3.33. 2-(4-Chloro-3-(pyridin-3-ylmethylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (45)
45 was synthesized by procedures A, H and J.
1H NMR (400MHz, DMSO-d6): d 13.78 (bs,1H), 9.21 (t, J¼ 5.9 Hz,
1H), 8.58 (d, J ¼ 2.3 Hz, 1H), 8.47 (dd, J ¼ 1.9, 4.7 Hz, 1H), 8.42 (dd,
J ¼ 1.5, 7.8 Hz, 1H), 8.32 (s, 1H), 8.09 (d, J ¼ 7.8 Hz, 1H), 7.76 (ddd,
J¼ 1.7, 1.9, 8.0 Hz,1H), 7.71 (d, J¼ 8.6 Hz,1H), 7.60 (d, J¼ 2.3 Hz,1H),
7.57 (dd, J ¼ 2.4, 8.6 Hz, 1H), 7.38 (dd, J ¼ 4.8, 7.8 Hz, 1H), 4.49 (d,
J ¼ 5.9 Hz, 2H).
ESI-MS m/z calcd for C22H14ClN3O5 (M þ H)þ 436.06; found:
436.22.
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ylmethylcarbamoyl)phenyl)isoindoline-5-carboxylic acid (46)
46 was synthesized by procedures A, C, H and J.
1H NMR (400 MHz, DMSO-d6): d 8.99 (t, J ¼ 5.7 Hz, 1H), 8.60 (s,
1H), 8.55 (s, 1H), 8.38e8.52 (m, 4H), 8.29 (s, 1H), 8.06 (d, J ¼ 7.7 Hz,
1H), 7.76 (d, J ¼ 8.0 Hz, 1H), 7.72 (d, J ¼ 8.0 Hz, 1H), 7.67 (s, 1H),
7.33e7.41 (m, 2H), 7.29 (d, J ¼ 9.1 Hz, 1H), 6.79 (d, J ¼ 8.9 Hz, 1H),
4.52 (d, J ¼ 5.8 Hz, 2H), 4.46 (d, J ¼ 5.9 Hz, 2H).
ESI-MS m/z calcd for C28H21N5O5 (M þ H)þ 508.15; found:
508.34.
4.3.35. 2-(4-(Hexylamino)-3-(hexylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (47)
47 was synthesized by procedures A, C, H and J.
1H NMR (400 MHz, DMSO-d6): d 8.42 (dd, J ¼ 1.4, 7.8 Hz, 1H),
8.30 (s, 1H), 8.25 (t, J ¼ 5.6 Hz, 1H), 8.07 (d, J ¼ 7.8 Hz, 1H), 8.03 (t,
J ¼ 5.5 Hz, 1H), 7.57 (d, J ¼ 2.4 Hz, 1H), 7.3 (dd, J ¼ 2.3, 8.8 Hz, 1H),
6.78 (d, J ¼ 8.97 Hz, 1H), 3.10e3.24 (m, 4H), 1.54e1.63 (m, 2H),
1.43e1.52 (m, 2H),1.35e1.42 (m, 2H),1.22e1.34 (m,10H), 0.82e0.91
(m, 6H).
ESI-MS m/z calcd for C28H35N3O5 (M þ H)þ 494.26; found:
493.97.
4.3.36. 2-(3-(3-Chloro-4-methylphenylcarbamoyl)-4-(piperidin-1-
yl)phenyl)-1,3-dioxoisoindoline-5-carboxylic acid (48)
48 was synthesized by procedures A, C, H and J.
1H NMR (400 MHz, DMSO-d6): d 11.40 (s, 1H), 8.41 (dd, J ¼ 1.4,
7.7 Hz, 1H), 8.31 (s, 1H); 8.07 (d, J ¼ 7.8 Hz, 1H), 8.02 (d, J ¼ 2.0 Hz,
1H), 7.82 (d, J ¼ 2.5 Hz, 1H), 7.57 (dd, J ¼ 2.6, 8.5 Hz, 1H), 7.49 (dd,
J ¼ 2.0, 8.2 Hz, 1H), 7.41 (d, J ¼ 8.8 Hz, 1H), 7.35 (d, J ¼ 8.1 Hz, 1H),
2.96e3.06 (m, 4H), 2.31 (s, 3H), 1.60e1.70 (m, 4H), 1.49e1.57 (m,
2H).
13C NMR (100.5 MHz, DMSO-d6): d 166.42, 166.36, 165.83,
164.64, 151.37, 138.04, 136.44, 136.36, 135.41, 133.17, 132.15, 131.42,
130.71, 130.17, 128.97, 128.85, 126.53, 123.75, 123.31, 120.56, 119.28,
118.01, 53.56, 25.92, 23.28, 18.99.
ESI-MS m/z calcd for C28H24ClN3O5 (M þ H)þ 518.14; found:
518.42.
4.3.37. 2-(3-(4-Methyl-3-(triﬂuoromethyl)phenylcarbamoyl)-4-
(piperidin-1-yl)phenyl)-1,3-dioxoisoindoline-5-carboxylic acid (49)
49 was synthesized by procedures A, C, H and J.
1H NMR (400MHz, DMSO-d6): d 13.75 (bs,1H), 11.52 (s, 1H), 8.42
(dd, J ¼ 1.3, 7.6 Hz, 1H), 8.31 (s, 1H), 8.25 (d, J ¼ 2.2 Hz, 1H), 8.08 (d,
J ¼ 7.7 Hz, 1H), 7.79e7.85 (m, 2H), 7.57 (dd, J ¼ 2.6, 8.7 Hz, 1H), 7.45
(d, J ¼ 8.5 Hz, 1H), 7.42 (d, J ¼ 8.9 Hz, 1H), 3.03 (t, J ¼ 4.6 Hz, 4H),
2.42 (s, 3H), 1.61e1.69 (m, 4H), 1.49e1.56 (m, 2H).
ESI-MS m/z calcd for C29H24F3N3O5 (M þ H)þ 552.17; found:
552.19.
4.3.38. 2-(3-(3-Fluoro-4-methylphenylcarbamoyl)-4-(piperidin-1-
yl)phenyl)-1,3-dioxoisoindoline-5-carboxylic acid (50)
50 was synthesized by procedures A, C, H and J.
1H NMR (400MHz, DMSO-d6): d 13.75 (bs,1H), 11.46 (s, 1H), 8.42
(d, J ¼ 7.8 Hz, 1H), 8.31 (s, 1H), 8.08 (d, J ¼ 7.8 Hz, 1H), 7.84 (d,
J¼ 2.6 Hz,1H), 7.74 (dd, J¼ 2.0, 12.2 Hz,1H), 7.57 (dd, J¼ 2.6, 8.6 Hz,
1H), 7.42 (d, J ¼ 8.6 Hz, 1H), 7.35 (dd, J ¼ 1.9, 8.3 Hz, 1H), 7.28 (app t,
J ¼ 8.5 Hz, 1H), 3.02 (t, J ¼ 4.5 Hz, 4H), 2.21 (s, 3H), 1.60e1.71 (m,
4H), 1.48e1.58 (m, 2H).
ESI-MS m/z calcd for C28H24FN3O5 (M þ H)þ 502.17; found:
502.23.
4.3.39. 2-(4-Morpholino-3-(p-tolylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (51)
1H NMR (400MHz, DMSO-d6): d 13.75 (bs,1H),10.92 (s,1H), 8.42(dd, J ¼ 1.5, 7.7 Hz, 1H), 8.31 (s, 1H), 8.08 (d, J ¼ 7.7 Hz, 1H), 7.77 (d,
J ¼ 2.5 Hz, 1H), 7.67 (d, J ¼ 8.5 Hz, 2H), 7.56 (dd, J ¼ 2.6, 8.6 Hz, 1H),
7.39 (d, J ¼ 8.7 Hz, 1H), 7.18 (d, J ¼ 8.5 Hz, 2H), 3.65e3.76 (m, 4H),
2.99e3.09 (m, 4H), 2.28 (s, 3H).
ESI-MS m/z calcd for C27H23N3O6 (M þ H)þ 486.16; found:
485.93.
4.3.40. 2-(4-(4-Methylpiperazin-1-yl)-3-(p-tolylcarbamoyl)
phenyl)-1,3-dioxoisoindoline-5-carboxylic acid (52)
52 was synthesized by procedures A, C, H and J.
1H NMR (400 MHz, DMSO-d6): d 10.97 (s, 1H), 8.41 (d, J ¼ 7.8 Hz,
1H), 8.31 (s, 1H), 8.05 (d, J ¼ 7.8 Hz, 1H), 7.78 (s, 1H), 7.66 (d,
J¼ 8.0 Hz, 2H), 7.56 (d, J¼ 8.6 Hz,1H), 7.40 (d, J¼ 8.6 Hz,1H), 7.18 (d,
J ¼ 7.9 Hz, 2H), 3.06e3.16 (m, 4H), 2.57e2.71 (m, 4H), 2.32 (s, 3H),
2.28 (s, 3H).
ESI-MS m/z calcd for C28H26N4O5 (M þ H)þ 499.19; found:
498.92.
4.3.41. 2-(4-(2-Methoxyethylamino)-3-(p-tolylcarbamoyl)phenyl)-
1,3-dioxoisoindoline-5-carboxylic acid (53)
53 was synthesized by procedures A, C, H and J.
1H NMR (400MHz, DMSO-d6): d 13.77 (bs,1H),10.01 (s,1H), 8.43
(dd, J ¼ 1.1, 8.0 Hz, 1H), 8.32 (s, 1H), 8.09 (d, J ¼ 7.7 Hz, 1H), 7.74 (m,
2H), 7.54 (d, J ¼ 8.1 Hz, 2H), 7.39 (dd, J ¼ 2.3, 8.9 Hz, 1H), 7.13 (d,
J ¼ 8.0 Hz, 2H), 6.89 (d, J ¼ 9.0 Hz, 1H), 3.57 (t, J ¼ 5.2 Hz, 2H),
3.33e3.40 (m, 2H), 3.31 (s, 3H), 2.27 (s, 3H).
ESI-MS m/z calcd for C26H23N3O6 (M þ H)þ 474.16; found:
474.20.
4.3.42. 2-(4-(2-(2-Methoxyethoxy)ethoxy)-3-(p-tolylcarbamoyl)
phenyl)-1,3-dioxoisoindoline-5-carboxylic acid (54)
54 was synthesized by procedures A, G, H and J.
1H NMR (400 MHz, DMSO-d6): d 10.16 (s, 1H), 8.42 (dd, J ¼ 1.4,
7.8 Hz, 1H), 8.31 (s, 1H), 8.08 (d, J ¼ 7.8 Hz, 1H), 7.91 (d, J ¼ 2.6 Hz,
1H), 7.56e7.68 (m, 3H), 7.39 (dd, J ¼ 8.9 Hz, 1H), 7.16 (d, J ¼ 8.1 Hz,
2H), 4.39 (bt, J ¼ 4.2 Hz, 2H), 3.89 (bt, J ¼ 4.1 Hz, 2H), 3.62 (dd,
J¼ 4.4, 5.6 Hz, 2H), 3.39 (dd, J¼ 4.4, 5.0 Hz, 2H), 3.15 (s, 3H), 2.28 (s,
3H).
ESI-MS m/z calcd for C28H26N2O8 (M þ H)þ 518.17; found:
518.89.
4.3.43. 2-(4-Methoxy-3-(p-tolylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (55)
1H NMR (400MHz, DMSO-d6): d 13.76 (bs, 1H), 10.15 (s, 1H), 8.41
(dd, J ¼ 1.4, 7.8 Hz, 1H), 8.30 (s, 1H), 8.08 (d, J ¼ 7.7 Hz, 1H), 7.70 (d,
J ¼ 2.6 Hz, 1H), 7.62 (d, J ¼ 8.1 Hz, 2H), 7.58 (dd, J ¼ 2.7, 8.9 Hz, 1H),
7.34 (d, J ¼ 8.9 Hz, 1H), 7.15 (d, J ¼ 8.1 Hz, 2H), 3.96 (s, 3H), 2.27 (s,
3H).
ESI-MS m/z calcd for C24H18N2O6 (M þ H)þ 431.12; found:
430.97.
4.3.44. 2-(4-Chloro-3-(p-tolylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (56)
1H NMR (400MHz, DMSO-d6): d 13.79 (bs,1H),10.57 (s,1H), 8.43
(dd, J ¼ 1.5, 7.7 Hz, 1H), 8.33 (s, 1H), 8.11 (d, J ¼ 7.7 Hz, 1H), 7.76 (d,
J ¼ 8.6 Hz, 1H), 7.68 (d, J ¼ 2.5 Hz, 1H), 7.56e7.64 (m, 3H), 7.16 (d,
J ¼ 8.4 Hz, 2H), 2.27 (s, 3H).
ESI-MS m/z calcd for C23H15ClN2O5 (M þ H)þ 435.07; found:
434.87.
4.3.45. 1,3-Dioxo-2-(4-(phenylamino)-3-(p-tolylcarbamoyl)phenyl)
isoindoline-5-carboxylic acid (57)
1H NMR (400MHz, DMSO-d6): d 13.77 (bs,1H),10.29 (s,1H), 9.23
(s, 1H), 8.44 (dd, J ¼ 1.5, 7.7 Hz, 1H), 8.33 (s, 1H), 8.10 (d, J ¼ 7.8 Hz,
1H), 7.81 (d, J ¼ 2.1 Hz, 1H), 7.56 (d, J ¼ 8.4 Hz, 2H), 7.38e7.48 (m,
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J ¼ 8.6 Hz, 2H), 7.02 (t, J ¼ 7.2 Hz, 1H), 2.27 (s, 3H).
13C NMR (100.5 MHz, DMSO-d6): d 166.55, 166.52, 165.81,
165.33, 144.02, 141.19, 136.57, 136.10, 135.58, 134.80, 132.94, 131.95,
131.21, 129.43, 128.97, 128.42, 123.83, 123.37, 122.30, 121.91, 120.65,
120.52, 119.94, 115.74, 20.49.
ESI-MS m/z calcd for C29H21N3O5 (M þ H)þ 492.15; found:
491.97.
4.3.46. 2-(3-(3-Ethylphenylcarbamoyl)-4-(phenylamino)phenyl)-
1,3-dioxoisoindoline-5-carboxylic acid (58)
58 was synthesized by procedures A, C, H and J.
1H NMR (400MHz, DMSO-d6): d 13.77 (bs,1H),10.30 (s,1H), 9.21
(s, 1H), 8.44 (dd, J ¼ 1.5, 7.7 Hz, 1H), 8.33 (s, 1H), 8.1 (d, J ¼ 7.8 Hz,
1H), 7.82 (d, J ¼ 2.3 Hz, 1H), 7.55 (t, J ¼ 2.0 Hz, 1H), 7.51 (dd, J ¼ 2.2,
8.2 Hz, 1H), 7.39e7.48 (m, 2H), 7.34 (t, J ¼ 7.8 Hz, 2H), 7.21e7.28 (m,
3H), 7.02 (t, J¼ 7.3 Hz,1H), 6.96 (d, J¼ 7.6 Hz,1H), 2.58 (q, J¼ 7.6 Hz,
2H), 1.16 (t, J ¼ 7.6 Hz, 3H).
13C NMR (100.5 MHz, DMSO-d6): d 166.62, 166.54, 166.52,
165.80, 144.13, 144.05, 141.19, 138.63, 136.57, 135.58, 134.79, 131.94,
131.25, 129.43, 128.47, 123.83, 123.45, 123.37, 122.32, 121.90, 120.53,
120.01, 118.06, 115.76, 28.26, 15.55.
ESI-MS m/z calcd for C30H23N3O5 (M þ H)þ 506.16; found:
506.24.
4.3.47. 2-(4-(Diethylamino)-3-(p-tolylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (59)
1H NMR (400MHz, DMSO-d6): d 13.72 (bs,1H),12.50 (s,1H), 8.42
(dd, J ¼ 1.5, 7.7 Hz, 1H), 8.32 (s, 1H), 8.09 (d, J ¼ 7.6 Hz, 1H), 8.07 (d,
J ¼ 2.6 Hz, 1H), 7.53e7.66 (m, 4H), 7.18 (d, J ¼ 8.6 Hz, 2H), 3.19 (q,
J ¼ 7.2 Hz, 4H), 2.29 (s, 3H), 1.03 (t, J ¼ 7.1 Hz, 6H).
ESI-MS m/z calcd for C27H25N3O5 (M þ H)þ 472.18; found:
471.95.
4.3.48. 2-(4-(Hexylamino)-3-(p-tolylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (60)
60 was synthesized by procedures A, C, H and J.
1H NMR (400 MHz, DMSO-d6): d 13.78 (bs, 1H), 10.00 (s, 1H),
8.43 (dd, J¼ 1.5, 7.7 Hz, 1H), 8.31 (s, 1H), 8.09 (d, J¼ 7.7 Hz, 1H), 7.74
(d, J¼ 2.4 Hz,1H), 7.68 (t, J¼ 5.0 Hz,1H), 7.54 (d, J¼ 8.5 Hz, 2H), 7.38
(dd, J ¼ 2.4, 8.8 Hz, 1H), 7.13 (d, J ¼ 8.7 Hz, 2H), 6.85 (d, J ¼ 9.0 Hz,
1H), 3.15e3.24 (m, 2H), 2.27 (s, 3H), 1.61 (quint, J ¼ 7.0 Hz, 2H),
1.25e1.45 (m, 6H), 0.88 (t, J ¼ 7.0 Hz, 3H).
13C NMR (100.5 MHz, DMSO-d6): d 167.14, 166.76, 166.73, 165.81,
149.30, 136.52, 136.24, 135.56, 134.78, 132.66, 132.00, 131.91, 129.01,
128.93, 128.91, 128.16, 123.76, 123.31, 120.77, 120.75, 117.89, 114.91,
111.38, 42.28, 30.99, 28.48, 26.25, 22.08, 20.47, 13.91.
ESI-MS m/z calcd for C29H29N3O5 (M þ H)þ 500.21; found:
500.34.
4.3.49. 2-(4-(Decylamino)-3-(p-tolylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (61)
61 was synthesized by procedures A, C, H and J.
1H NMR (400 MHz, DMSO-d6): d 13.74 (bs, 1H), 9.99 (s, 1H), 8.43
(dd, J ¼ 1.5, 7.7 Hz, 1H), 8.31 (s, 1H), 8.09 (d, J ¼ 7.8 Hz, 1H), 7.74 (d,
J ¼ 2.4 Hz, 1H), 7.69 (t, J ¼ 4.8 Hz, 1H), 7.54 (d, J ¼ 8.4 Hz, 2H), 7.38
(dd, J ¼ 2.3, 8.8 Hz, 1H), 7.13 (d, J ¼ 8.4 Hz, 2H), 6.84 (d, J ¼ 9.0 Hz,
1H), 3.13e3.24 (m, 2H), 2.27 (s, 3H), 1.54e1.65 (m, 2H), 1.15e1.45
(m, 14H), 0.85 (t, J ¼ 6.4 Hz, 3H).
ESI-MS m/z calcd for C33H37N3O5 (M þ H)þ 556.27; found:
555.98.
4.3.50. 1,3-Dioxo-2-(4-(propylamino)-3-(p-tolylcarbamoyl)phenyl)
isoindoline-5-carboxylic acid (62)
62 was synthesized by procedures A, C, H and J.1H NMR (400MHz, DMSO-d6): d 13.74 (bs,1H),10.00 (s,1H), 8.43
(dd, J ¼ 1.4, 7.8 Hz, 1H), 8.32 (s, 1H), 8.09 (d, J ¼ 7.7 Hz, 1H), 7.75 (d,
J ¼ 2.4 Hz, 1H), 7.71 (t, J ¼ 5.5 Hz, 1H), 7.54 (d, J ¼ 8.4 Hz, 2H), 7.38
(dd, J ¼ 2.3, 8.9 Hz, 1H), 7.13 (d, J ¼ 8.1 Hz, 2H), 6.86 (d, J ¼ 9.0 Hz,
1H), 3.13e3.21 (m, 2H), 2.27 (s, 3H), 1.57e1.69 (m, 2H), 0.98 (t,
J ¼ 7.4 Hz, 3H).
ESI-MS m/z calcd for C26H23N3O5 (M þ H)þ 458.16; found:
457.87.
4.3.51. 1,3-Dioxo-2-(4-(piperidin-1-yl)-3-(pyridin-3-
ylmethylcarbamoyl)phenyl)isoindoline-5-carboxylic acid (63)
63 was synthesized by procedures A, C, H and J.
1H NMR (400 MHz, DMSO-d6): d 9.89 (t, J ¼ 5.9 Hz, 1H), 8.62 (s,
1H), 8.48 (d, J ¼ 4.7 Hz, 1H), 8.4 (d, J ¼ 7.5 Hz, 1H), 8.28 (s, 1H), 7.95
(d, J ¼ 7.6 Hz, 1H), 7.77e7.84 (m, 2H), 7.51 (dd, J ¼ 2.6, 8.8 Hz, 1H),
7.33e7.42 (m, 2H), 4.56 (d, J ¼ 5.6 Hz, 2H), 2.83e2.93 (m, 4H),
1.38e1.54 (m, 6H).
ESI-MS m/z calcd for C27H24N4O5 (M þ H)þ 485.17; found:
485.41.
4.3.52. 2-(4-Bromo-3-(p-tolylcarbamoyl)phenyl)-1,3-
dioxoisoindoline-5-carboxylic acid (64)
1H NMR (400MHz, DMSO-d6): d 13.78 (bs,1H),10.54 (s,1H), 8.43
(d, J ¼ 7.8 Hz, 1H), 8.32 (s, 1H), 8.10 (d, J ¼ 7.8 Hz, 1H), 7.90 (d,
J ¼ 8.5 Hz, 1H), 7.65 (d, J ¼ 2.4 Hz, 1H), 7.59 (d, J ¼ 8.1 Hz, 2H), 7.53
(dd, J ¼ 2.3, 8.5 Hz, 1H), 7.16 (d, J ¼ 8.0 Hz, 2H), 2.28 (s, 3H).
ESI-MS m/z calcd for C23H15BrN2O5 (M þ H)þ 479.02; found:
478.81.
4.3.53. 2-((4-(Piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)
carbamoyl)terephthalic acid (65)
65 was synthesized by procedures A, C, H and N.
1H NMR (400 MHz, DMSO-d6): d 13.06 (bs, 1H), 12.20 (s, 1H),
10.62 (bs, 1H), 8.25 (d, J ¼ 2.7 Hz, 1H), 8.10 (dd, J ¼ 1.9, 7.8 Hz, 1H),
8.05 (s, 1H), 7.95 (d, J¼ 8.0 Hz,1H), 7.87 (dd, J¼ 2.6, 8.8 Hz, 2H), 7.66
(d, J ¼ 8.4 Hz, 2H), 7.39 (d, J ¼ 8.7 Hz, 1H), 7.19 (d, J ¼ 8.5 Hz, 2H),
2.89e2.98 (m, 4H), 2.29 (s, 3H), 1.66e1.76 (m, 4H), 1.51e1.61 (m,
2H).
ESI-MS m/z calcd for C28H27N3O6 (M þ H)þ 502.19; found:
501.92.
4.3.54. 4-((4-(Piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)
carbamoyl)isophthalic acid (66)
66 was synthesized by procedures A, C, H and N.
1H NMR (400 MHz, DMSO-d6): d 12.20 (s, 1H), 8.34 (s, 1H), 8.24
(d, J ¼ 2.7 Hz, 1H), 8.05 (d, J ¼ 7.3 Hz, 1H), 7.88 (dd, J ¼ 2.7, 8.8 Hz,
1H), 7.77 (d, J ¼ 8.0 Hz, 1H), 7.66 (d, J ¼ 8.4 Hz, 2H), 7.38 (d,
J ¼ 8.8 Hz, 1H), 7.19 (d, J ¼ 8.3 Hz, 2H), 2.90e2.98 (m, 4H), 2.29 (s,
3H), 1.66e1.75 (m, 4H), 1.51e1.61 (m, 2H).
ESI-MS m/z calcd for C28H27N3O6 (M þ H)þ 502.19; found:
501.96.
4.3.55. 2-(4-(Piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)-1H-
benzo[d]imidazole-5-carboxylic acid (71)
71 was synthesized by procedures A, C, H, O, P, Q and R.
1H NMR (400 MHz, DMSO-d6): d 10.63 (s, 1H), 8.44 (d, J¼ 2.4 Hz,
1H), 8.29 (dd, J¼ 2.4, 8.9 Hz,1H), 8.24 (s,1H), 8.03 (d, J¼ 8.6 Hz,1H),
7.81 (d, J¼ 8.9 Hz,1H), 7.66 (d, J¼ 8.1 Hz, 2H), 7.41 (d, J¼ 8.4 Hz,1H),
7.19 (d, J ¼ 8.1 Hz, 1H), 5.73 (s, 1H), 3.08e3.16 (m, 4H), 2.29 (s, 3H),
1.59e1.68 (m, 4H), 1.49e1.57 (m, 2H).
13C NMR (100.5 MHz, DMSO-d6): d 167.05, 165.45, 154.17, 151.28,
136.76, 136.52, 133.63, 132.87, 130.69, 129.92, 129.46, 128.55, 127.27,
126.01, 119.58, 119.48, 115.71, 115.47, 114.01, 52.43, 25.61, 23.43,
20.62.
ESI-MS m/z calcd for C27H26N4O3 (M þ H)þ 455.20; found:
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4.3.56. 2-(4-(Piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)
benzofuran-5-carboxylic acid (77)
77 was synthesized by procedures A, C, H, O, S, T and R.
1H NMR (400MHz, DMSO-d6): d 12.89 (bs, 1H), 11.15 (s, 1H), 8.25
(dd, J¼ 2.3, 6.1 Hz,1H), 8.01 (dd, J¼ 2.2, 8.6 Hz,1H), 7.91 (dd, J¼ 2.0,
8.6 Hz, 1H), 7.73 (d, J ¼ 8.6 Hz, 1H), 7.68 (d, J ¼ 8.5 Hz, 2H), 7.52 (s,
1H), 7.37 (d, J ¼ 8.6 Hz, 1H), 7.19 (d, J ¼ 8.3 Hz, 2H), 2.99e3.06 (m,
4H), 2.29 (s, 3H), 1.61e1.69 (m, 4H), 1.50e1.56 (m, 2H).
13C NMR (100.5 MHz, DMSO-d6): d 167.42,164.67,156.52,156.03,
152.13, 136.50, 132.52, 129.38, 129.14, 127.92, 126.49, 125.91, 123.51,
122.91, 120.55, 119.37, 111.04, 101.66, 53.55, 25.84, 23.35, 20.53.
ESI-MS m/z calcd for C28H26N2O4 (M þ H)þ 455.19; found:
455.30.
4.3.57. 2-(4-(Piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)-1H-
indole-5-carboxylic acid (78)
78 was synthesized by procedures A, C, H, O, S, T and R. (Note:
methyl 3-iodo-4-(2,2,2-triﬂuoroacetamido)benzoate (76) was used
instead of 75 in procedure T.)
1H NMR (400 MHz, DMSO-d6): d 12.39 (bs, 1H), 11.98 (s, 1H),
11.36 (s, 1H), 8.29 (d, J ¼ 2.4 Hz, 1H), 8.21 (s, 1H), 7.99 (dd, J ¼ 2.4,
8.3 Hz, 1H), 7.66e7.75 (m, 3H), 7.43 (d, J ¼ 8.6 Hz, 1H), 7.40 (d,
J ¼ 8.6 Hz, 1H), 7.20 (d, J ¼ 8.3 Hz, 2H), 7.03 (d, J ¼ 1.4 Hz, 1H),
2.96e3.09 (m, 4H), 2.29 (s, 3H), 1.62e1.73 (m, 4H), 1.46e1.59 (m,
2H).
13C NMR (100.5 MHz, DMSO-d6): d 168.48, 164.80, 150.73,
139.77, 138.59, 136.53, 132.72, 129.51, 128.99, 128.58, 128.35, 127.00,
126.74, 122.93, 122.73, 122.05, 121.08, 119.56, 111.13, 99.74, 53.88,
25.95, 23.29, 20.61.
ESI-MS m/z calcd for C28H27N3O3 (M þ H)þ 454.21; found:
454.20.
4.3.58. 2-(4-(Piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)-2H-
indazole-6-carboxylic acid (80)
80 was synthesized by procedures A, C, I and U.
1H NMR (400 MHz, DMSO-d6): d 13.04 (s, 1H), 11.37 (s, 1H), 9.25
(s, 1H), 8.47 (d, J ¼ 2.8 Hz, 1H), 8.37 (s, 1H), 8.21 (dd, J ¼ 2.9, 8.6 Hz,
1H), 7.85 (d, J ¼ 8.7 Hz, 1H), 7.70 (d, J ¼ 8.4 Hz, 2H), 7.62 (dd, J ¼ 1.2,
8.8 Hz, 1H), 7.48 (d, J ¼ 8.8 Hz, 1H), 7.20 (d, J ¼ 8.4 Hz, 2H),
2.99e3.07 (m, 4H), 2.29 (s, 3H), 1.62e1.72 (m, 4H), 1.49e1.59 (m,
2H).
13C NMR (100.5 MHz, DMSO-d6): d 167.62, 163.86, 151.38, 148.17,
136.35, 134.85, 132.61, 129.65, 129.50, 129.38, 124.26, 123.30,
122.06, 121.57, 121.45, 121.07, 120.29, 119.39, 53.58, 25.87, 23.26,
20.49.
ESI-MS m/z calcd for C27H26N4O3 (M þ H)þ 455.20; found:
455.14.
4.3.59. 2-(4-(Piperidin-1-yl)-3-(p-tolylcarbamoyl)phenyl)-2H-
indazole-5-carboxylic acid (81)
81 was synthesized by procedures A, C, I and U.
1H NMR (400 MHz, DMSO-d6): d 12.84 (s, 1H), 11.38 (s, 1H), 9.35
(s, 1H), 8.49 (s, 1H), 8.46 (d, J ¼ 2.8 Hz, 1H), 8.20 (dd, J ¼ 2.8, 8.8 Hz,
1H), 7.82 (dd, J ¼ 1.6, 9.0 Hz, 1H), 7.77 (d, J ¼ 9.3 Hz, 1H), 7.69 (d,
J ¼ 8.4 Hz, 2H), 7.49 (d, J ¼ 8.9 Hz, 1H), 7.20 (d, J ¼ 8.6 Hz, 2H),
2.99e3.08 (m, 4H), 2.30 (s, 3H), 1.63e1.73 (m, 4H), 1.49e1.58 (m,
2H).
13C NMR (100.5 MHz, DMSO-d6): d 167.46, 163.86, 151.18, 149.88,
136.32,134.81,132.63,129.60,129.37,126.39,125.08,124.49,124.24,
123.28, 121.96, 121.88, 121.53, 119.42, 117.26, 53.63, 25.84, 23.20,
20.49.
ESI-MS m/z calcd for C27H26N4O3 (M þ H)þ 455.20; found:
455.08.4.3.60. 5-(2H-Indazol-2-yl)-2-(piperidin-1-yl)-N-(p-tolyl)
benzamide (82)
82 was synthesized by procedures A, C, I and U.
1H NMR (400 MHz, DMSO-d6): d 11.50 (s, 1H), 9.12 (s, 1H), 8.48
(d, J ¼ 2.8 Hz, 1H), 8.18 (dd, J ¼ 2.9, 8.8 Hz, 1H), 7.74 (dd, J ¼ 8.5,
16.8 Hz, 2H), 7.69 (d, J¼ 8.5 Hz, 2H), 7.47 (d, J¼ 8.8 Hz,1H), 7.31 (dd,
J ¼ 6.6, 8.9 Hz, 1H), 7.20 (d, J ¼ 8.8 Hz, 2H), 7.10 (dd, J ¼ 6.6, 8.5 Hz,
1H), 2.96e3.06 (m, 4H), 2.29 (s, 3H), 1.62e1.73 (m, 4H), 1.48e1.58
(m, 2H).
13C NMR (100.5 MHz, DMSO-d6): d 163.82, 151.01,148.92, 136.38,
135.28, 132.59, 129.62, 129.41, 126.76, 123.05, 122.53, 122.07, 121.80,
121.59, 121.45, 120.89, 119.38, 117.38, 53.68, 25.92, 23.26, 20.51.
ESI-MSm/z calcd for C26H26N4O (M þ H)þ 411.21; found: 411.22.
4.4. Enzymatic activity assay
All LPL activity measurements were performed using Intralipid®
as substrate as described previously [21]. Compounds (1 mL in
DMSO) or pure DMSO (in controls) were added to 49 mL of assay
buffer (50 mM potassium phosphate pH 7.4 containing 0.15 M NaCl
and 0.01% (v/v) Triton X-100). The N-terminal part (a.a. 26e184) of
recombinant human ANGPTL4 (5 mL of 900 nM ANGPTL4 in assay
buffer yielding a ﬁnal concentration of 75 nM) and bovine LPL (5 mL
of 180 nM LPL in assay buffer yielding a ﬁnal concentration of
15 nM) were then added. Addition of Triton X-100 to the assay
buffer was a derivative of our initial HTS campaign to prevent the
rate of frequent hitters as recommended by Feng and Shoichet [50].
In addition the detergent served to prevent precipitation of the
compounds and also increased the potency of ANGPTL4 in terms of
inactivating LPLdthus lowering the tight-binding limit of the assay.
The mixtures were incubated for 10 min at 25 C in 96-well mi-
crotiter plates (Nunc, Cat No. 236108) on an orbital shaker
(600 rpm). The remaining LPL activity was then determined by
addition of 90 mL of substrate mix with the following ﬁnal con-
centrations: 0.15 M Tris, pH 8.5, 0.1 M NaCl, 6% BSA, 5% heat-
inactivated rat serum, 16.7 units of heparin/mL, and Intralipid®
corresponding to 2 mg TG/mL. The LPL-mediated hydrolysis was
stopped after 45 min by addition of Triton X-100 to a ﬁnal con-
centration of 2.5% (v/v). The released fatty acids were quantiﬁed
using the kit NEFA HR2 (Wako Chemicals). The activity is reported
as normalized percent of control, ((sample mean) (mean negative
control))/((mean positive control)  (mean negative control))*100
where the negative control is DMSO þ LPL þ ANGPTL4 and the
positive control is DMSO þ LPL only. In the doseeresponse analysis
the ratio between LPL and the new batch of ANGPTL4 was adjusted
to achieve the same level of inactivation as in previous
experiments.
4.5. Plasma protein binding
We utilized Rapid Equilibrium Dialysis (RED) device inserts
which allow for short dialysis times (2e4 h) as compared to
traditional methods (>8 h) and minimal drug consumption in a 96-
well format. Pooled human plasma was provided by Uppsala Aca-
demic Hospital and was collected from two male and two female
donors (non-smoking). In brief, 0.2 mL of the plasma test solution
with typically 10 mM ﬁnal compound concentrationwas transferred
to the membrane tube in the RED insert. Then 0.35 mL isotonic
phosphate buffer pH 7.4 was added to the other side of the mem-
brane. The 96-well base plate was then sealed with an adhesive
plastic ﬁlm (Scotch Pad) to prevent evaporation. The plate was
incubated with rapid rotation (z900 rpm) on a Kisker rotational
incubator at 37 C for 4 h to achieve equilibrium.
A stability test of the test solution was also prepared (to allow
detection of drug degradation). For this, 100 mL of the plasma test
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37 C for 4 h (as long as the dialysis time). The plasma test solution
was frozen directly after the administration to prevent degradation.
After incubation, the contents of each plasma and buffer
compartment were removed and immediately frozen until analysis.
Prior to LCeMS/MS analysis the samples were mixed with equal
volumes of control buffer or plasma as appropriate to maintain
matrix similarity for analysis. Plasma proteins were then precipi-
tated by the addition of methanol (1:4) containing Warfarin as
analytical internal standard. The plate was then sealed, centrifuged
and the supernatant was analyzed by mass spectrometry (LCeMS/
MS). The following system was used: Waters XEVO TQ triple-
quadrupole mass spectrometer (electrospray ionization, ESI)
coupled to a Waters Acquity UPLC (Waters Corp.). For chromato-
graphic separation a general gradient was used (1% mobile phase B
to 90% over 2min total run) on a C18 BEH 1.7 mmcolumn 2 50mm
(Waters Corp.). Themobile phase A consisted of 5% acetonitrile 0.1%
formic acid and the mobile phase B 100% acetonitrile 0.1% formic
acid. The ﬂow ratewas 0.5 ml/min. 5 mL of the sample were injected
and run with the mass spectrometric settings reported in Table 1.
For analyses of plasma protein binding or Caco-2 permeability a
standard curve between 1 and 1000 nM was prepared. No detailed
method validation was performed and an accurate limit of detec-
tion is therefore not known. The method sensitivity was however
very good with an estimated limit of detection <1 nM. Analysis of
chemical/metabolic stability does not require a standard curve
since it is quantiﬁed on a relative basis. Chemical/metabolic sta-
bility in plasma was quantiﬁed on a relative basis.4.6. Kinetic solubility
All testing was made from a 10 mM DMSO stock solution and
analysis with LCeMS/MS as described below. Studies on solubility
were performed in PBS (pH 7.4) and in an HCl-adjusted PBS to low
pH, approximately pH 1.2. The study was performed by addition of
1 mL DMSO stock per 100 mL buffer, (1% DMSO, theoretical maximal
detectable solubility ¼ 0.1 mM) and incubation at 37 C for 2 h in
sealed glass vials. After the incubation an aliquot of the solution
was transferred to a glass vial insert and centrifuged at 10,000 g,
37 C, for 20 min.4.7. Caco-2 permeability
The Caco-2 study was performed in accordance with published
protocols [39]. Caco-2 cell monolayers (passage 94e105) were
grown on permeable ﬁlter support and used for transport study on
day 21 after seeding. Prior to the experiment a drug solution of
10 mM was prepared and warmed to 37 C. The Caco-2 ﬁlters were
washedwith pre-warmed Hank's balance salt measurement (HBSS)
prior to the experiment, and thereafter the experiment was started
by applying the donor solution on the apical side. The transport
experiments were carried out at pH 6.5 in the apical chamber,
reﬂecting the pH of the intestinal lumen, and pH 7.4 in the baso-
lateral chamber reﬂecting the pH of the blood. The experiments
were performed at 37 C and with a stirring rate of 500 rpm. The
receiver compartment was sampled at 15, 30 and 60 min, and at
60 min also a ﬁnal sample from the donor chamber was taken in
order to calculate the mass balance of the compound.
Directly after the termination of the experiment the ﬁlter inserts
were washed with pre-warmed HBSS and the membrane integrity
was checked. This was performed by transepithelial electrical
resistance (TEER) measurement and by measurement of Mannitol
permeability, which is a paracellular marker used for integrity
measurements.4.8. Metabolic stability
Themicrosomal metabolic stability assay utilized pooled human
or animal species, liver microsomes (LM) with supplemented
cofactor (NADPH) to facilitate CYP reactivity against target com-
pound. Human hepatocytes (HHep) were freshly prepared at
UDOPP (liver from surgery at the academic hospital in Uppsala on
the same day). For incubation, target compound (1 mM in the in-
cubation) and LM (0.5 mg/ml) or hepatocytes (0.5  106 cells/ml)
were diluted in 0.1 M phosphate buffer pH 7.4 (LM) or Williams
medium E (HHep). The incubation volume was 150 mL. The reaction
with LM was initiated with addition of NADPH (1 mM incubation
concentration) in buffer or by the addition of cells with HHep. The
incubation times were 0, 5, 15, 40 min (in duplicate for LM) or 0, 10,
30, 60 min (in duplicate for HHep) and the reaction was quenched,
at each time point, by addition of 100 mL acetonitrile containing
Warfarin as the analytical internal standard. The plate was then
sealed, centrifuged and frozen at 20 C until LCeMS/MS analysis.
4.9. Animal procedures and in vivo experiments
Female C57B16/J mice (Taconic, Denmark) aged 8e9 weeks with
an average weight of 18 g were used for the in vivo experiments
(n ¼ 8/group). The mice were housed at room temperature with
free access to tap water and standard rodent diet at 12:12 h light
cycle with the light off at 18.00e06.00. The mice were treated for 3
consecutive days with 0.5 mL intraperitoneal injections of PBS (pH
7.4), DMSO (3%, v/v) and Triton X-100 (0.2%, v/v), containing 1 mM
compound. On the 3rd day the mice were fasted 8 h frommidnight
and injected a ﬁnal 4th time in themorning. One hour after the ﬁnal
injection the mice were given a 0.2 mL oral olive oil gavage. Blood
samples were collected from the tail vein in EDTA coated capillary
tubes at baseline and for every 60 min until 180 min. The blood was
immediately centrifuged (þ4 C for 10 min at 1500 RCF) and the
plasmawas stored at 80 C. After the ﬁnal blood sample, the mice
were sacriﬁced.
Plasma was analyzed with Trig/BG (Roche/Hitachi, Mannheim,
Germany) in microtiter plates according to manufacturer
instructions.
The local animal ethics committee at Umeå University approved
all animal experiments (case number: A54/11).
Statistics were calculated using GraphPad Prism (GraphPad
Software, Inc, La Jolla, CA) or Student's t-test for repeated measures
unless otherwise stated.
5. Nuclear receptor proﬁling
Compound 80 was proﬁled at ten concentrations against the
nuclear receptors FXR, PPARa, PPARg, and RXRa for agonist activity
using the Life Technologies' SelectScreen® Proﬁling Service (www.
lifetechnologies.com). For all receptors EC50 values exceeded
100 mM.
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